

Immunological Memory of Viral Infections: Mechanisms, Durability, and Implications for Protective Immunity —A Review

Dhefah Hameed Al-mudhafer¹, Eman Hassani AL-Salami²

, Saif Jabbar Yasir³

^{1,2,3} Department of Medical Microbiology, College of Medicine, University of Kufa, Najaf, Iraq. Email: dhifaf.almudhaffer@uokufa.edu.iq¹, emanh.alsalami@uokufa.edu.iq², saif.alshehmani@uokufa.edu.iq³

Abstract:

Immune memory is a cornerstone of protective immunity against viral infections, enabling rapid and enhanced responses upon re-exposure to viruses. This review focuses on the interrelated roles of memory B cells, memory T cells, follicular helper T cells (Tfh), and cytokine signaling in maintaining long-term immunity, providing a comprehensive overview of the processes, longevity, and outcomes of immune memory. CD8⁺ cytotoxic T cells and CD4⁺ helper T cells are memory T cells that facilitate viral clearance and regulate the immune response, while memory B cells rapidly differentiate into plasma cells, enabling effective antibody-mediated protection. Germinal center interaction facilitates the formation of long-lasting memory B cells and plasma cells, and follicular helper T cells (Tfh) are essential for this process. Here, we explore how epigenetic regulation of T cell development can influence the establishment and maintenance of immunological memory and discuss in-depth on TCF-1 signaling pathways that play an active role in memory T cell population sustenance. T cell depletion is another important barrier to the retention of efficacious immunological memory, particularly in scenarios of chronic viral infection. Importantly, even though they are exhausted, exhausted T cells likely remain capable of functionally traversing the TCF-1⁺ progenitor pool with the possibility for future therapeutic targets. Importantly, this study demonstrates the significance of both humoral immunity (e.g.: antibodies and memory B cells) as well as cellular immunity (e.g.: memory T cells) to control infections and disease severity. Along with inducing

short-term antibody responses, the results indicate that future vaccine strategies should aim to develop functional memory B cells and long-lived plasma cells, as well as stem-like T cell populations for broad and durable protection. Furthermore, reversing T-cell depletion through epigenetic manipulation could, in principle, improve immunotherapy outcomes and vaccination efficacy in cancer and chronic viral infections. These findings offer valuable insights into the interconnected network supporting immune memory and suggest strategies to mitigate the challenges posed by immune depletion in chronic infections—information crucial for future immunotherapy regimens and vaccine development efforts.

Keywords: Immunological Memory, Memory B Cells, Memory T Cells, Immune Memory Durability, Immune Reprogramming, Epigenetic Modulation, Protective Immunity

Introduction:

A key feature of adaptive immunity is its ability to mount a rapid and robust response upon subsequent exposure to pathogens. This capacity, known as immunological memory, is the foundation of long-term protection against future disease. Immunological memory—activating memory B cells, memory T cells, and other immune components—provides faster and more precise protection than the initial immune response. This robust and long-lasting immune memory is shaped by a wide range of interactions between cellular and humoral immunity, molecular biology, and epigenetics. Humoral immunity, however, relies on similar memory B cells, as demonstrated by the reinfection of the host with highly affinity antibodies that have eliminated the virus. These B cells can undergo a process called affinity maturation, adapting to keep pace with changes in the virus and remaining viable long after the initial infection has cleared. Another key player in viral control are memory T cells which comprise both CD8⁺ cytotoxic T cells and CD4⁺ T helper cells, important for the coordination of immune responses as well as direct destruction of infected cells. T follicular helper (Tfh) cells are indispensable for promoting the generation and long-term maintenance of memory B cells in germinal centers to provide sustained antibody production and durable immunity. Humoral and cellular immunity are known to be involved in the formation of memory, but whether this is short- or long-lived immunity remains a matter of controversy. Epigenetic regulation, cytokine signaling and

transcription factors such as TCF-1 affect memory cell longevity. Some exhausted T cells can persist for many years in the system, but are functionally incompetent which makes the maintenance of immunological memory a challenge during chronic infections with viruses. However, despite being exhausted T cells, the TCF-1⁺ progenitor fatigued T cells retain some potential for self-renewal and thus may be valuable targets for immunotherapeutic targeting.

How strongly immune memory lasts and for how long varies between different individuals; it is determined by age, the immunological condition experienced during the timeframe of infection, genetic predispositions and infectious agent type. Chronic viral infections, for instance, could impair the quality of immune responses leading to impaired immune memory and increased prevalence of pathologic antibodies. The relationship between memory B cells and (Te)Fh cells in the generation and maintenance of immunological memory. These results provide insights into the factors that relate to protective immunity and lay further groundwork toward improving cancer immunotherapy and vaccine design, particularly against latent viruses and chronic infections.

Importance of Immunological Memory in Viral Protection

Immunological memory, encompassing aspects of so-called memory B cells, antibodies, and specialized T cell subsets, is critical to long-term immune protection against viral infection and vaccination [1,2]. This robust immunological recall therefore has its own operational state [3], where B and T cells are primed for rapid, potent memory when re-exposed to a disease or vaccine. TRC mobilize pre-programmed memory cells that produce virus specific neutralizing antibodies and robust effector cells, eliciting a stronger and more rapid immune response, preventing or minimizing illness after exposure [4]. Memory B cells maintain humoral immunity by rapidly generating protective antibodies following pathogen infection [5]. Upon re-infection, memory B cells that express T-bet and antigen-experienced receptors proliferate and differentiate into IgG⁺ antibody-secreting plasmablasts [6]. This quicker process of differentiation elicits a more powerful and targeted immunological response than the primary encounter, neutralizing viral particles to mitigate the progression of illness [7]. This rapid response is important to control viral replication and reduce disease severity and duration [8]. There is evidence that SARS-CoV-2 neutralizing antibodies wane

several months following infection [9]. Yet memory B cells against SARS-CoV-2 clonal expand for many months post-infection which indicates continued germinal center activity for antibody generation and affinity maturation [10]. Upon viral re-exposure, these memory B cells exit germinal centers and rapidly expand in an affinity-dependent manner to form tough plasma cells that merely secrete antibodies [11]. This strong recall response also leads to the generation of high affinity, broadly neutralizing antibodies that pose better protection against viral variants [12]. Reactivation involves helped B cells and CD8⁺ T cells that directly kill virally infected cells, or CD4⁺ T cells that help B [13] Memory T lymphocytes residing in mucosal tissues work to inhibit viral spread at the sites of reinfection, such protective immunity [14]. Memory T cells proliferate rapidly after encountering cognate antigens, and they execute effector functions in a CD4⁺ T cell cytokine-mediated activation of other immune cells as well as CD8⁺ T cell cytolytic activity to kill infected host cells [15]. In addition to these direct effector functions, memory B and T cells form a strong and diverse compartment of immunological memory that can adaptively respond to changing viral challenges via affinity maturation and broadly neutralizing antibody production [16]. The presence of such a well-armored humoral and cellular immunological memory results in an effective virus entry prevention and control over the established disease [17]. Antibodies can neutralize viruses immediately, but T cells clear infected cells and limit severity of disease when humoral immunity is low [18].

Together, these findings suggest that long-lasting viral protection is mediated by immunological memory. Studies also show that it accelerates a better response of the immune system to similar viral antigens. Therefore, it is not only through antibodies that protection is mediated (memory B cells and neutralizing antibodies as well as CD4⁺ helper T cells, CD8⁺ cytotoxic T cells and tissue-resident memory cells). They reduce viral replication, the severity of illness, and days well as the duration of infection and host survival. Challenge in correcting the incorrect notion that antiviral immunity primarily relies on antibody levels. While neutralization depends upon antibodies in the early phase of infection, memory B and T cells play an important role even after a decline in antibody levels. Therefore, the evaluation of immunity status should consider cellular immunity, memory cell quality and circulating antibodies.

Mechanisms of Immunological Memory Formation

Antigens are responsible for forming immunological memory activated naïve B and T cells differentiate into different memory subsets in response to antigen exposure [19]. This is tightly regulated so as to generate long-lived plasma cells, memory B cells, effector and central memory T-cells within germinal centers [20,21]. Subsets of these effector T lymphocytes are recognized according to their specificity for either MHC class I (which is presented primarily to CD8⁺ T cells that kill virally infected cells) or MHC class II (recognized by both CD4⁺ T lymphocyte subsets that assist in B cell maturation and provide support in addition to other helper signals required for CD8⁺ T activity, [22]. CD4⁺ T cell help potentiates both CD8⁺ T and B cell responses during antiviral immunity via production of cytokines and direct cellular contacts [23-25]. Upon activation, CD4⁺ T lymphocytes proliferate and differentiate into effector cells; a small fraction becomes long-lived memory cells that are capable of responding rapidly to subsequent viral contacts [26]. Most recovered SARS-CoV-2 patients had robust CD4⁺ T cell responses, which are critical for antibody production and cytotoxic CD8⁺ T cell activation [27]. In addition to direct effector functions, CD4⁺ T helper cells, especially T follicular helpers, are required for germinal center formation and the generation of high-affinity antibodies and memory B cells [28]. CD8⁺ T cells can differentiate into central and effector memory T cells with distinct migratory patterns and functional abilities required to protect against viral infections [29].

The development of immune memory involves a series of precisely coordinated immune events, such as antigen recognition, activation of naïve lymphocytes, clonal proliferation, differentiation of effector cells, cell shrinkage, and the persistence of selected populations of memory cells. Germline responses lead to the emergence of memory B cells and long-lived plasma cells, while activated T cells differentiate into tissue-stabilized, central, effector, and memory subsets. Memory development is understood as a process, not a single event. The link between antigen exposure and specialized memory populations is evident in the fact that this subheading contains its most powerful sections. The process is best understood in a more linear fashion: antigen presentation, lymphocyte activation, clonal proliferation, effector response, shrinkage, and memory retention.

The process of immune memory formation has been extensively studied and is known to involve a series of finely coordinated immune events, including antigen recognition, activation of naïve lymphocytes, clonal proliferation, differentiation of effector cells, a regression phase where responder cells either disappear or acquire effector function, and the survival of selected populations of memory cells. Germline responses produce long-lived memory B cells and plasma cells, while activated T cells differentiate into tissue-stabilized, central, effector, and memory subsets. This suggests that memory development is a dynamic process over time, not a single experience. This title is best suited when linked to antigen exposure in specialized memory populations. A clearer version of this section would be: antigen presentation – lymphocyte activation – expansion/clonal proliferation – effector cell responses – regression and memory maintenance.

Role of T Cells in Antiviral Memory

T cells are essential for mediating cytotoxicity against infected cells, helping to activate B cells, and maintaining protective immune memory during antiviral immunity [30]. Helper T cells (CD4+) exert their control over cellular and humoral immunity through cytokine production and direct cell communication [31]. They enhance the cytotoxicity of CD8+ T cells, memory formation, neutralizing antibody synthesis, and long-lived plasma and memory B cell growth [32]. Converted naïve CD8+ T cells develop into effector cytotoxic T lymphocytes that generate antiviral cytokines such as TNF- α and IFN- γ , and also include granzymes and perforin, which act to help eradication of the virus [33]. CD4+ T cells attracted CD8+ T cells to the site of infection, and opened up draining lymph nodes to naïve B and T cells, amplifying the antiviral response [34]. Despite the complexities, interactions of CD4+ and CD8+ T cells guide a well-orchestrated response to clearing acute viral infections with long-term memory [35]. SARS-CoV-2 specific T cells CD4+ and CD8+ memory T cells are long lived in SARS-CoV-2, with CD4+ constituting a T central memory echo Type that possesses strong helper function, durability and thus longevity and CD8+ which are terminally differentiated effector memory producing IFN-gamma TNFalpha as well granzyme B [36,37]. During acute viral infections, antigen-specific CD8+ T lymphocytes expand rapidly and differentiate into effector cells that secrete these cytokines to eliminate pathogens [38].

Following the contraction phase that follows an acute infection, a fraction of effector T cells continues to maintain during long-term and are differentiated into memory T cells with distinct phenotypes [39]. Following pathogen exposure, big boosts robust recall responses are supposed to be given by these memory T cells [40]. SARS-CoV-2-specific CD4⁺ T cells produce IL-2 and TNF- α , there are essential for maintaining long-term T cell memory, while CD8⁺ T cells have a more restricted and less diverse cytokine profile indicating a direct cytotoxic role rather than strong recall functions [41]. This diversity, including SARS-CoV-2-specific CD8⁺ T cells that are cross-reactive with seasonal coronaviruses, may be important in viral clearance, particularly among individuals with limited neutralizing antibody responses; however, the phenotype of these tetrameric-enhanced CD8⁺ T cells appears to have become functionally depleted [42]. This polymorphic cellular response highlights the importance of T cell-mediated cellular immunity in controlling viral infections, since CD8⁺ T cell activation can occur independently of CD4⁺ T cells under certain conditions (e.g., following a strong type I interferon response [43]). While CD4⁺ and CD8⁺ T cells are capable of broadly independent activation, their long-term functions in adaptive immunity against viral infections largely depend on their subsequent differentiation into various memory cell subsets (44, 45). The mechanisms for maintaining these distinct populations of T memory cells and their longevity, specifically the role of tissue-resident memory cells in proliferative history and their impact on long-term protective capacity, still require further investigation [46]. To understand why T memory cells are effective against newly emerging viral variants, one must better examine the transcriptional and genetic programming that facilitates their phenotypic plasticity and functional diversity.

Antiviral memory requires T cells. Helper T cells (CD4⁺) coordinate the immune response by promoting B cell maturation, antibody production, and facilitating cytotoxicity of cytotoxic T cells (CD8⁺). Cytotoxic T cells (CD8⁺) kill virus-infected cells via cytolytic mechanisms (perforin and granzyme B) and release antiviral cytokines (interferon-gamma and tumor necrosis factor-alpha). Memory T cells add another dimension to this process, as they are more capable of rescuing the body from severe disease. One of the most important aspects of this paper focuses on antiviral cellular immunity. This discussion is crucial because T cell memory provides protection at another level, where antibody responses are less effective or when dynamic viral

variants escape neutralization. The second subheading could be improved by distinguishing between central memory T cells, active memory T cells, and tissue-resident memory T cells, given the different locations, functions, and protective roles of these three groups.

B Cell Contributions to Long-Term Immunity

Antiviral immunity relies on antibody production by B cells and their functional differentiation into antibody-secreting plasma cells and memory B cells. Plasma cells are the antibody factories that provide immediate protection, and memory B cells rapidly differentiate into plasma cells or antibody-secreting cells upon exposure to the specific pathogen, enabling a strong and rapid secondary immune response. A robust memory B response is essential in SARS-CoV-2 infection to maintain antibody levels [47]. However, the mechanisms that regulate and maintain memory B cells, particularly their epigenetic programming and targeting patterns within lymphoid organs, remain unclear [46]. In-depth understanding of the factors that drive B cells to differentiate into either germinal center-derived plasma cells or memory B cells can provide insights for improving strategies to vaccinate [49]. By characterizing these pathways, it may be possible to develop vaccination platforms to generate longer living humoral responses with broader protective potential [50]. The antigen specificities and protective potential of B lymphocytes generated following viral infection or immunization, such as tick-borne encephalitis virus (TBEV), remains to be fully determined [51]. Massive changes in the B cell lineage trajectories and chromatin accessibility were described for SARS-CoV-2 immunity, showing unique adaptive immunological memory mechanisms [52] compared to healthy controls. In contrast, long-lived plasma cells provide immediate antibody-mediated protection [53,45], while memory B cells are able to rapidly differentiate and switch to mature effector states to combat emerging strains of viruses. Long-life plasma cells and memory B cells construct a robust humoral immunity with neutralizing antibodies against infections [55]. Germinal centers are the sites where B cells go through somatic hypermutation and selection for improved antigen-binding affinity to generate memory B cells [56].

Humoral immunity requires B cells to differentiate into long-lived plasma cells and memory B cells. Plasma cells secrete antibodies persistently, and memory B cells stand ready for activation when an infection occurs. Affinity, Memory B Cells Aid Adaptive

Immunity to New Virus Types Because they can differentiate and mature. The subtitle also does a good job of explaining why falling antibody levels are not necessarily an indicator of losing immunity. Upon viral re-infection, we have memory B cells that can rapidly generate antibody secreting plasmablasts. The section could employ a clearer comparison of the distribution, longevity, and immune activity in plasma and memory B cells.

Cytokine Signaling in Memory Development

How low Tfh help directs germinal center B cells toward memory over plasma cell fates is not understood [57]. This leads to the proliferation and differentiation of short-lived antibody-secreting plasma cells, rather than triggering long-term memory development in germinal center B cells due to poor T cell-B cell synergy [58]. High-affinity memory B cells and long-lived plasma cells [59] must arise from germinal centers in order to mediate durable humoral immunity after either vaccination or spontaneous infection. Somatic hypermutation and selection in germinal centers give rise to increasing affinity B lymphocytes able to recognize variant epitopes that is necessary for controlling pathogens that evolve quickly [60]. These memory B cells, upon encounter with antigen subsequently differentiate into various populations that express tissue residency markers, suggesting immune response plasticity [61]. This process depends on germinal center T follicular helper cells and B cells to enhance affinity maturation and diversify B cell. In contrast, aberrant regulation of GC dynamics can lead to defective mBC production or even autoreactive antibodies. T follicular helper cells provide signals and cytokines that stimulate B cell class switch recombination, somatic hypermutation, and affinity maturation in germinal centers [62]. After ChAdOx1 nCoV-19 immunization, studies showed that this complex cellular interaction produces high-affinity plasma blasts and long-lived protective memory B lymphocytes [63]. Germinal center B cell proliferation — and differentiation to high-affinity antibody production — is enabled by co-stimulatory signals, including CD40 engagement and cytokines such as IL-4 and IL-21 [64,65].

Germinal centers are formed by T follicular helper CD4 T cells, allowing for selection of high-affinity B cells and generating memory B and plasma cells with class switch recombination as well as somatic hypermutation [66-68]. The formation of germinal centers has not been observed in fatal COVID-19 cases, concomitantly with

severely reduced Tfh cell development indicating their important function for immune protection [69]. Within the germinal center, T follicular helper cells can direct B cell activation, proliferation, and selection through intricate signaling [70]. Cellular Prerequisites for Memory and Recall Process and Requirements: CD40L in T follicular helper cells is also required to help germinal center B cells differentiate into high-affinity antibody-producing plasma cells or rapid recall of affinity-matured memory B cells [71]. This study implicates that the productivity of activated B and T cells during memory formation is dictated by specific cytokine signaling. T follicular helper cells provide CD40L, IL-4 and IL-21 from which they undergo specific signals regulating class-switch recombination, somatic hypermutation, affinity maturation and B cell differentiation to memory or plasma cells. Germinal center cells communicate accurately to regulate memory formation. Hence, scientists care about this subheading it reveals that T-cell-driven immunological memory is not infection but the molecular signaling of immunity through T cell driven pathways. Antibody durability relies on Tfh–B cell contact. It would help if the signals originating from cell–cell contact could be distinguished from cytokine-mediated signals in this section.

Durability of Immunological Memory to Viral Infections

T follicular helper cells are known to be critical for germinal cell formation and memory B cell generation; however, peripheral blood cTfh cells can serve as a surrogate marker of germinal center activity and antibody longevity [72-74]. CXCR5, ICOS, CD28, PD-1, CD40L, SAP and Bcl-6 facilitate these cells in their interactions with germinal center B cells [75]. In the context of viral infections, circulating Tfh cells are strongly associated with germinal center responses and neutralizing antibody titers against SARS-CoV-2 [76-77]. These circulating Tfh cells that express a high level of Bcl-6 and co-express CXCR5, PD-1, ICOS are the ones providing help to germinal center B cells by secreting IL-21 and IL-4 which provide signals for B cell differentiation, class switching, and affinity maturation [78,79]. They possess a series of conserved cell surface markers across species such as CCR7^{lo}, CXCR5^{hi}, PD-1^{hi}, CTLA-4^{hi}, ICOS^{hi} DP1^{lo} CD95^{hi} CD40L^{hi} and Bcl-6^{hi} [80]. Circulation of Tfh cells has been linked to development of immune responses, and unique subsets have been identified as potentially performing specific functions; for instance, CXCR3-expressing Tfh cells appear to be Th1-oriented and may control the establishment of persistent viral infections like HIV [81,82]. Interactions of T follicular helper cells and germinal

center B cells that depend upon antigen presentation, produce rounds of B cell clone proliferation as well as pathways of differentiation into memory B cells and long-lived antibody-secreting plasma cells [83].

As a result, continuous interaction between T follicular helper cells and B cells helps antigen retention by follicular dendritic cells which further selects and matures B cells in germinal centers [84]. Since these TFH cells are predominantly located in secondary lymphoid organs, the direct tracking of these cells is challenging in human studies [85]. Indeed, circulating T follicular helper (cTFH) cells found in peripheral blood, and characterized by surface markers such as CXCR5 and PD-1 are an excellent surrogate of systemic Tfh activity which correlates with antibody responses as well [84], although the functional equivalence between cTFH cells and germinal center Tfh cells is still being established [86]. Circulating TFH cells are germinal center TFH cells and facilitate T-dependent B-cell maturation and antibody production [87]. TFH cell markers, which include CXCR5, PD-1, and ICOS as well as increase lymphoid tissue homing and B cell help [88]. Because of their migratory potential driven by CXCR5 and CXCL13, Tfh cells can potentially rapidly accumulate into B cell follicles to elicit the germinal center reaction [89]. Particularly following influenza vaccination, the ICOS over-expression on circulating CXCR5⁺ Tfh cells parallels the robust antibody responses suggesting that these cells play an important role in vaccine induced immunity [90]. This study suggests that monoclonal antibodies, nucleic acid vaccines and entered pathogens are influenced by germinal center reactions, memory B and T cells, antigen exposure and host factors on the persistence of immune memories. Circulating T follicular helper cells are an indicator of germinal center activity and antibody persistence, particularly after viral infection or immunization. For this part, it is translational because it connects the basic immunology and vaccine evaluation. So having circulating Tfh cells would be a good thing because it could predict for antibody persistence. Vigilance is paramount because circulating Tfh cells may not behave as germinal center Tfh cells in lymphoid organs. Think of them as an indirect but helpful indicator.

Factors Influencing Memory Lifespan

Immunological memory is influenced by Tfh-B cell interaction strength, the cytokine environment that germinal center reactions occur within, and the nature of

antigen persistence or re-exposure [91]. Tfh cells located in the germinal center play a crucial role in promoting the production of memory B cells and long-lived plasma cells, both essential components of humoral immunity [92]. The phenotypic and functional diversity of memory Tfh cells (particularly the Tfh1, Tfh2, and Tfh17 subsets) likely contributes to the varying outcomes of immune memory maintenance [93]. CXCR3-expressing Tfh1 cells are frequently found at sites of condensed antibody production following vaccination [94] and induce IgG2a and IgG3 antibody responses that provide protection against viral infection. By assisting in the switching of certain serotypes, Tfh2 cells induce the switching of IgE and IgG1 classes, while Tfh17 cells may contribute to the regulation of inflammatory responses and mucosal immunity [95]. The phenotypic diversity of Tfh cells demonstrates their ability to adapt flexibly and finely regulate the humoral immune response, influencing both serum antibody formation and B cell memory [96]. During the decline in germinal center responses, the expression of PD-1, CXCR5 and Bcl6 diminishes, indicating that memory Tfh cells arising from activated Tfh cells are essential for providing long-lasting humoral immune protection [97]. The mechanisms through which memory Tfh cells are maintained and recalled remain poorly understood, particularly with respect to their rapid re-engagement of germinal center responses upon secondary antigen exposure [98]. Despite this progress, factors such as aging, microenvironmental polarity, repeated vaccination, immunodeficiency and the immunosuppressive pathways triggered by drugs against autoimmune disease will hamper Tfh cell responses and high-affinity antibody production and maintenance required for vaccine adequacy [99]. In contrast, T follicular helper cells are temporally and spatially regulated in germinal centers, where they interact with follicular dendritic cells to present antigen, and these interactions regulate B cell activation which affects both the duration of antibody responses as well as immunological memory [100].

Tfh17 cells have not only the unique ability to support germinal center formation but also evidence indicates that they may be more effective than Tfh1 or Tfh2 at maintaining the immunological memory associated with humoral immunity [101]. One such indicator of functional specialization is the different capacity for memory keeping across Tfh subsets, a finding that highlights their complex contributions to long-term protective immunity in settings requiring sustained antibody production [102]. Those specific Tfh cell subsets were subsequently found to be essential for germinal center

dynamics, affinity maturation and humoral immunity characterized by expression of CXCR5 and BCL6 [103]. They facilitate the differentiation of B cells into high-affinity antibody secreting plasma cells and memory B cells [104,105] via critical cell–cell contacts and through cytokine signaling. Recent studies have discovered a similar CD62L + and low PD-1 memory-like Tfh cell population that manifest as precursors to effector Tfh cells in recall responses with improved long-term survival and expression of stemness-associated genes [106]. Memory Tfh cells rapidly re-engage humoral immunity after antigen exposure for an effective antibody response [107]. To induce effective and durable humoral immunity, vaccine strategies must promote mechanisms underlying T-follicular helper (Tfh) cell development and persistence, especially as they relate to the cytokine dependency, transcriptional programs associated with memory-like Tfh cells. These data begin to infer mechanisms impacting on longevity of immunological memory via antigen persistence, repetitive exposure as well as age and immune status at iodugerminal center quality and Tfh subset activity and immunosuppressive conditions. Subsets of Tfh cells, such as Tfh1, Tfh2 and Tfh17 cells may impact on antibody quality and duration. Understanding how immunological memory varies between individuals is beneficial in this regard. In others, protection lasts longer after infection or vaccination. In some individuals such as immunocompromised or immunosuppressed populations, and in older adults, the relationship between neutralization titer and clinical protection may not ap.... This would be more useful with clinical examples.

Protection provided by memory B cells is mediated through antibody production upon secondary exposure to the same pathogen and can also endure for lengthy periods of time, along with T cells which do cell killing and pre-existent immunologic memory [10]. Memory T cells, I infer from only memory cytokines that are normal homeostatic ones e.g. Homeostatic memory T cells survive and proliferate under the influence of cytokines such as interleukin–7 (IL-7) and IL-15, whereas stem-like features are maintained through transcription factors such as T cell factor 1 (TCF-1), which also play a role in self-renewal and long-term recall.

Maintenance of Memory T Cells

The survival and rapid recall function of memory T cells, especially T follicular helper (TFH) cells, require distinct cytokine environments and regulatory

transcriptional networks. Homeostatic proliferation and antigen-independent quiescence of central and effector memory T lymphocytes require interleukin-7 and IL-15. Recently, it has been observed that long-lived Tfh cells may be especially prone to NAD-induced cell death during preparation for mass spectrometry analysis [108], which could further explain the underestimation of long-lived humoral immune responses in previous studies. Memory T cells, especially CD8⁺ cytotoxic T cells, play a major role in the clearance of infected cells and reducing disease severity. Both help the immune system respond fast and effectively during reinfection. Specific antibody immune responses depend on the survival and activity of Tfh cells, so their full characterization undoubtedly requires innovative research methods [109]. Tfh cell lineage commitment and functional flexibility are a dynamic interaction between cytokine availability and transcription factor expression, affecting the quantity, quality, and persistence of humoral immune responses [110]. TCF-1 is a stem cell-associated transcription factor that promotes Tfh cell persistence and memory in support of humoral immunity [111], and is thus part of this regulatory network. TCF-1 is a "core" transcription factor expressed in naïve and memory T cells, suggesting its role in determining cell fate outside the Tfh domain [112, 113]. Antibody production and germinal center persistence depend on the expression of Tfh stem cell and progenitor cell characteristics [114]. The strength of this subheading lies in the fact that it addresses not only memory formation but also the persistence of memory cells. The importance of TCF-1, as a transcription factor associated with self-renewal capacity and long-term viability of T cells, adds depth to the subject. A precise definition of the section would help keep cytokine-dependent survival and transcription factor-dependent memory programming separate.

Persistence of Memory B Cells and Antibody Production

Long-lived plasma and memory B cells are important for humoral immunity after acute viral infections [9]. These cells continuously secrete antibodies in some niches in the bone marrow and secondary lymphoid organs, or give rise to antibody-secreting cells within days of re-exposure to a pathogen, thereby providing rapid protection against reinfection. In fact, there can be substantial variability in antibody responses even among patients with the same severity of illness highlighting how intrinsic characteristics of the host and exogenous factors shape the adaptive immune response [115]. Circulating T follicular helper (cTfh) cells are key determinants of neutralizing

antibody levels and long-lasting immunity following viral infections and immunization [116]. CXCR5+PD-1+ T cells consist a source of co-stimulation and cytokine support to induce strong B cell responses, as well as supporting germinal center development, affinity maturation, and giving rise to long-lived plasma and memory B cells [117]. TCF-1 is important in Tfh cells for driving more stem-like states less mature with roles specific to germinal center responses and high-affinity antibody production [118]. The Role of Cytokine and Epigenetics in Memory Development: Important for the development of memory B cells and memory T cells are the signals provided by cytokines released by Tfh [118,119]. Epigenetic control is critical for developing and maintaining immune memory, especially in the presence of chronic infections. This highlights the requirement for better techniques to isolate and characterize these memory cells in order to properly assess their numbers and function. TCF-1 is critical for memory T cell differentiation and stemness T cell-regulatory programs, self-renewal capacity of stem-like T cells, leading to generation of long-lasting effector subsets and in turn a persistent immune response during acute and chronic infections [119,120].

In animal models, TCF-1 is required for survival of CD8+ T cells during continuous stimulation and strong memory recall responses after without infection or immunization [121]. TCF-1 preserves a progenitor pool that replenishes exhausted T cells, thereby mitigating immunological collapse and contributing to viral containment [122]. TCF-1 expression is critically important for distinguishing regenerative versus terminally differentiated populations of fatigued T cells during the early stages of chronic infection [123]. Results suggest TCF-1+ memory-like cells are capable of both proliferation and self-renewal, replenishing depleted effector T cells specific to the antigen and mediating viral control [124,125]. TCF-1 is also a repressor of type I interferon signaling, and functionally can lead to depletion in T cells [126]. A pre dysfunctional population of TCF-1+CXCR5+CD8+T cells expressing Slamf6 and PD-1 can expand (and even re-expand) in antigen-free host replenishing the exhausted CD8+T cell pool in chronic viral infections [127]. The stem-like TCF-1+ CD8+ T cells that also express high levels of the transcriptional factor 1 and the CXC motif chemokine receptor 5, have a self-renew property and slow attrition to become effector cells under chronic antigen exposure functions by sustaining immune response [128]. This population of TCF-1+ T cell is necessary for antiviral immunity and act as a source to restore all

stimulated T-cell responses upon blockade of programmed death-1 pathway [129,130]. TCF1⁺ T-cells are the precursors of terminal fatigued effector cells by self-renewing and differentiating away from an effector cell state in chronic viral infections [131]. This TCF-1-expressing progenitor population is necessary for the generation and maintenance of these depleted effector cells during chronic infections [132].

These data suggest that humoral immunity against a viral pathogen such as the one studied here likely relies on sustaining memory B cells and long-lived plasma cells. Long-lived plasma cells secrete antibodies at a constant rate, whereas memory B cells recall rapidly upon re-exposure. Widespread germinal center activity, limited Tfh support and host intrinsic factors as well as transcriptional regulation control antibody persistence. In contrast, this subtitle reinforces the importance of antibody number, affinity and abundance as well as variety and memory B cell recall for durable humoral immunity. The first type are important discussions around TCF-1 and fatigue in CD8⁺ T cells. To this end, B cells, plasma cells, antibody persistence and humoral recall reactions should dominate this subtitle.

Implications for Protective Immunity

Because modalities to alter the processes that determine progenitor fatigued T cells could improve the efficiency of adoptive cell transfer approaches (133), knowledge of these processes is important for future development of immunotherapies for chronic viral infection and malignancy. T_{PEX} cells express TCF-1, SLAMF6 and CXCR5 due to this persistent viral infection or tumor progression, enabling them to survive better than terminally exhausted T cells [134,135]. TCF-1⁺ progenitor exhausted cells have a stem-like identity and proliferate, but differentiate into effector-like cells that actively regulate viral loads to maintain immune responses [136,137]. These cells represent a potential therapeutic target to reverse T-cell fatigue [25]. The persistent requirement of these progenitor depleted T lymphocytes for CD28 co-stimulation to maintain their mitochondrial fitness and self-renewal capacity opens this pathway as a major regulatory mechanism underlying chronic antiviral immunity [138]. T_{PEX} are TCF-1⁺/PD-1⁺ stem-like progenitor exhausted T cells that can self-sustain and give rise to a variety of exhausted T-cell populations, implicating their requirement for responses to immune checkpoint blockade [139,140]. Notably, TCF-1 also acts to branch the fate of self-renewing versus fully-differentiated exhausted T cells during chronic infection

[141], preventing terminal effector differentiation and enhancing progenitor exhaustion through regulation by PD-1. This regulatory framework maintains an equilibrium between a renewable progenitor reservoir and effector differentiation to avert immunopathology following chronic antigenic exposure [142]. CD8⁺ effector T cells with co-expression of TCF1, CD62L and MYB are stem-like fatigued T cells that have increased self-renewal and multipotency, which are required for preserving the CD8⁺ T cell response to chronic infection [142]. These progenitor-tired T cells also express differentiation markers such as TOX and BATF, as well as checkpoint inhibitors like PD-1 but have decreased proliferation and cytokine production, suggesting they are epigenetically locked in a exhausted state [144].

Forceful appropriated progenitor exhausted T cells, provided they are TCF1⁺, can self-renew and respond to immune checkpoint inhibitors [145,146], whereas Williamson and colleagues recently reported that CD8⁺PD-1⁺Lin[−] dormant stem cell-like memory T cells serve as a rich source of antigen-responsive effector CD8⁺T cells, drawing attention either to regulatory activity mediated by PD-1/PD-Lpairing or the subversion of the dysfunctional state--the antagonism between exhaustion and functional adaptation in this more complex but complete form is yet-to-be-evaluated. TCF-1+PD-1^{lo} Tex Cell Cluster, A Precursor Population of Terminally Differentiated Tex Cells [147] Self-Renews and Sustains T Cell Responses in Chronic Infections and Malignancies TCF-1 expression is also required for the initiation and maintenance of stemness in exhausted T cells, supporting a model wherein CD8⁺ T cell exhaustion is controlled by this transcription factor [148]. Protective immunity is influenced by immunological dysfunction and memory formation Summary B and T lymphocytes underlie rapid recall and protection in acute viral infections. Antigen exposure leads to the exhaustion of T cells during chronic viral infections. Continuous activation of TCF-1⁺ progenitor fatigued T cells may drive self-renewal and preservation of antiviral responses. This subtitle is an advanced one because it says fatigued T lymphocytes are not utterly useless. Fatigued progenitor-like cells are able to continue controlling the immune microenvironment and responding to immunotherapy. Real protective memory T cells vs. progenitor fatigued T cells must be differentiated because they are distinct biological entities in an immunological state as well. Immunological memory produced by the future vaccines should be broad, long-lasting and have functional features. The goal of a successful vaccine would be to enhance short-lived antibody production, long-

lived plasma and memory B cells, functional CD4⁺ and CD8⁺ T cells with potentially stem-like features with prolonged recall. Thus, the vaccine design should be taken into account humoral and cellular immunity. This subtitle is important because it extends the evaluation of vaccines from antibody titers to immunological durability. Others, such as epigenetic reconditioning of exhausted T cells, are more under the umbrella of immunotherapy as opposed to vaccine development. Due to this, the study that was shown above suggest splitting this indication into vax and immunological reprogramming/immunotherapy approaches.

Vaccine Development Strategies

Progenitor fatigued TCF-1⁺ progenitors support immunological responses in chronic infection, and vaccine development should target their generation and persistence. This requires knowledge of the molecular and cellular pathways that drive their differentiation and expansion, which cells come from where, and with what antigens [149]. Such knowledge is key for designing vaccine platforms to elicit potent and long-lived TCF-1⁺ progenitor responses that improve durable viral immunity. In particular, manipulating expression of TCF1 could enhance T cell proliferation and thus checkpoint blockade therapy by shifting the population away from progenitor depleted T cells [150]. Elucidation of how TCF1 and TOX control the epigenetic and transcriptional program of T cells could also provide strategies for new immunomodulatory interventions to prevent or reverse T cell exhaustion [151,152]. The developmental history of exhausted T cells and the role of the reciprocal functional circuitry imparted by TCF1-TOX interaction could provide additional epigenetic methods to convert dysfunctional T-cells into progenitor-like state. This approach restored their proliferative capacity and responsiveness to immune checkpoint blockade, enhancing protection against chronic viral infection and tumor pathology [154]. As the response to immune checkpoint blockade relies on TCF-1 and TIM-3 expression, reprogramming may include co-inhibitory receptors as targets [155]. TCF-1 retains stem-like functions and upregulates Bcl2 expression through c-Myc, indicating an intricate regulatory network for T cell survival and differentiation of progenitor depleted T cells [156]. Above all, HMGB2 regulates the development of fatigued CD8⁺ T cell and stemness during chronic viral infections [157]. Therefore, modulating HMGB2 expression or activity could be a means to enhance the dendritic cell progenitor properties of depleted T cells for therapeutic purposes. Both TCF1 and

EGR2 required for stability of the progenitor cell identity thereby preventing differentiation into effector-like cells which would limit long-term persistence [158]. Collectively, this sophisticated regulatory network indicates that it is possible to manipulate TCF1+ T cells to retain or enhance a stem-like phenotype for an effective therapy and long-term efficacy in chronic disease [159].

Immune checkpoint blockade exerts its effects mainly through TCF1+ progenitors in chronic viral infections and various tumors, but it is also dependent on the sensitivity of programmed death-1 receptor therapy [150]. T-cell-based cancer immunotherapy must appropriately interrupt early epigenetic remodeling initiated within hours after tumor antigen contact that causes the first appearance of dysfunction [161], and ideally induce silencing and outgrowth-stimulating T-cells [8]. This study must unravel the molecular mechanisms that set-up and maintain the depleted T cell epigenetic landscape [162,163]. Targeting the processes through which epigenetic changes such as ID2 mediate T cell fatigue development and function may therefore represent novel means for therapeutic intervention [164]. Therefore, future research should focus on identifying the epigenetic regulators and chromatin modifiers that govern tired T cell plasticity and function as potential targets for innovative strategies to reinvigorate immune cells. This includes exploration of transcription factors such as NR4A, TOX and IRF4 that regulate expression of inhibitory receptors and terminal differentiation, and TCF-1 with accumulates progenitor fatigued T-cells [165]. Mechanistically understanding how these transcription factors interact with epigenetic machinery such as histone demethylases (e.g., lysine-specific demethylase 1) that sustain stemness in progenitor exhausted T cells will be important for the application of pathway inhibition or transcriptional activation therapy targeting terminal differentiation to improve therapeutic outcome [166]. Knowledge of epigenetic processes that maintain the exhausted phenotype (TOX and NR4a) are necessary for devising rejuvenating strategies to improve T-cell recall (167). This also involves learning how prolonged TCR stimulation induces NFAT to express TOX generate a maintained chromatin state of exhaustion, limiting the blocking of PD-[168]. Epigenetic changes such as DNA methylation and histone abnormalities that contribute to a deficient T cell functional capacity deserve investigation for therapeutic targets through the elucidation of the underlying molecular mechanisms [169,170]. Vaccines of the future must elicit broad, durable and functional immune memory. An effective vaccine must induce short-lived

antibody as well as long-term plasma and memory B cells, functional CD4⁺ and CD8⁺ T cells, and perhaps stem-like T cells with longevity, allowing for great recall capacity. Thus, it is important to think about humoral and cellular immunity in vaccine design. This subtitle is very important because it makes the impact of the vaccine assessment not just through antibody titers, but through immunological durability. Certain tactics, such as epigenetic control of exhausted T cells, are also less relevant to vaccine development than to immunotherapy more broadly.

Memory Responses to Re-infection

Having immunological memory is necessary for a fast and efficient protection against the same pathogen following infection. This protection is mediated by long-lived memory T and B cells, which are more sensitive and have undergone transcriptional and epigenetic changes compared with naive cells. Such long-lasting, broad protection is mediated by these specialized immune cells through immediate memory responses, improved effector functions, and long-term survival [171]. Antigen exposure during the course of a primary infection leads to the generation of varied memory subsets with distinctive migratory and effector attributes (a process that requires complex developmental pathways). In chronic viral infections, T-cell depletion can disrupt protective memory responses leading to poor viral control and greater disease risk [172]. An epigenetic study described that T cells with this invigorated phenotype have a distinct and stable lineage, which is defined by unique chromatin accessibility patterns in HIV-1 and HCV infections [173]. In contrast, CMV-specific CD8⁺ T lymphocytes have greater access to memory-specific genomic regions, which illustrates context-dependent differences in epigenetic programming associated with persistent antigen [174]. The exceptionally "stiff" chromatin and global methylation programming of exhausted CD8 T cells prevent re-programming to functional memory even after PD-1 blockade, indicating an epigenetic lock on the cellular fate that limits recall responses [157-177]. A distinct form of epigenetic landscaping (mostly DNA hypermethylation) harbors ineffective gene expression and preserves exhaustion-mediated immune-nonresponsiveness [178].

In contrast, epigenetic states enable rapid reactivation and strong effector functions in an effector (and memory) T cell [179]. Memory T-cell subsets exhibit coordinated epigenetic re-organization and changes in metabolic features that enhance memory

response to antigen re-exposure [180]. It is the basis for my assumption that secondary immune responses are faster, more powerful and more efficient than primary immune responses. This would produce memory B cells that quickly produce antibodies and memory T cells, which secrete cytokines and kill infected targets. Depletion of T cells and stable epigenetic changes can impair memory responses and protective immunity in chronic viral infections. The difference between protective recall immunity and immunological failure following a chronic infection is the basis of this subtitle which is why it has some significant value. The section would be improved by direct comparisons of acute diseases (i.e. influenza or SARS-CoV-2) vs chronic infections such as HIV, HBV, HCV So this would tell readers how type of virus affects memory.

Challenges in Immunological Memory Research

Although progress has been made in understanding immunological memory, significant challenges remain, particularly with respect to the processes involved in determining protection longevity and quality during natural life cycle aspects of specific pathogens or host populations. Disparities in memory T-cell subset classification are difficult to overcome since memory populations exhibit different phenotypic and functional properties that correspond to longevity and protective capacity [191]. This should also include dissection of the dynamic interplay between epigenetic changes and transcriptional networks in these subsets, as well as their contribution to differential memory potential [182]. Mem-T cell subsets are defined at present using a small number of surface markers which only partially reflects the detailed functional and epigenetic states that determine long-living Proteomes [183]. ATAC-seq, ChIP-seq and RNA-seq are examples of single-cell multi-omics methods that are fundamental to deciphering the complicated epigenetic circuitry Fulfilling CTL heterogeneity and dysfunction when comparing intratumorally CTLs versus healthy ones [184]. In this regard, the first step to enhancing memory T cell lifetime and function is understanding how these epigenetic changes (most notably DNA methylation and histone modifications) are generated and maintained during memory differentiation [185]. More studies are warranted to determine the role of epigenetic regulatory mechanisms such as accessible chromatin states at cytokine gene loci and enhancer regions in memory T cell rapid recall [186,187]. Further research into the epigenetic and genetic regulatory networks involved in immunologic memory formation will require future methylation and gene expression studies [188]. Spatial epigenomic technologies will

also help to gain insight into the tissue-specific signals that shape epigenetic programming and resident memory populations [189,190]. Regulation of epigenetic landscapes by cytokine eco-systems and antigenic stimulation will inform memory cell plasticity and fate. For this reason, it is essential to investigate how these epigenetic changes are maintained through cell divisions, in order to protect memory T-cell identities and function. A comprehensive knowledge on epigenetic programming has been revealed which could help develop precise immunotherapeutic strategies to bypass T-cell depletion and promote effective long-term protective immunity [191]. Distinct proteasome signatures have been identified between progenitor and terminally exhausted T cells by single-cell multi-omic profiling (consisting of both scRNA-seq and bulk ATAC-seq) indicating the high importance of epigenetic programming to T cell fate and function [192].

Progressive exhaustion differentiation leads to extensive programming of the transcriptome and epigenome that culminates in a stable, non-proliferative state characterized by expression of multiple inhibitory receptors for prolonged time periods [193]. Epigenetic alterations (both DNA methylation and histone modifications stabilize gene expression profiles that define this exhausted phenotype [194]. Infection with effector T cells generates a population of microbes, causing epigenomic changes that contribute to both the clinical features and propagation process via memory-driven differentiation, reproduction fitness in relation to persistence exhausted into reactivation techniques as well as limited immune functionality has become replacing specialized selectivity and epigenetic adjustments. Therefore, this highlights the requirement of therapies that reverse fatigued T lymphocytes to recreate epigenetic landscapes [152,197]. Therefore, the molecular mechanisms underlying T cell depletion should be defined, especially to memory CD8⁺ T cells with sustained activation [198]. To this end, it is necessary to learn how chromatin modifiers such as EZH2, DNA methyltransferases and histone chaperone CAF-1 regulate gene expression programs at specific stages of the immune response that dictate memory versus exhaustion [199]. Studies are needed to clarify the chronological relationship of histone post-translational changes and de novo DNA methylation with respect to terminal exhaustion [200].

Here we provided an overview of immunological memory research problems: Key challenges faced in the field include defining heterogeneity of memory cells,

identifying reliable biomarkers that predict protection, dynamism and epigenetic regulation of donor T cell membranes, distinguishing between memory and exhaustion signals, targeting antigen-specific immune responses, as well as emerging technologies such as single-cell RNA sequencing together with ATAC-seq / ChIP-seq profiling mass-cytometry based spatial multi omics technology. These methods are required to understand immunological memory at cellular and molecular levels. This subtitle is important because it mirrors the limits of what can be gained through immunological research. It is difficult to identify memory cell function with the traditional surface markers. That said, it might be helpful to classify the problems in this section into biological, methodological and clinical/translational categories.

Future Directions and Unanswered Questions

Studies are needed to determine what extrinsic factors, for example prolonged antigen exposure, co-stimulatory/inhibitory signals and/or cytokine milieu activate these epigenetic changes and T cell exhaustion in case of chronic infections or malignancies [201]. These enigmatic marks (histone modifications and DNA methylation patterns) must be inherited and maintained through multiple T cell divisions in the setting of continuous antigen stimulation, but it is unclear how this process is regulated. This includes investigating how chromatin accessibility and three-dimensional genomic architecture undergo dynamic changes that stabilize T cell exhaustion, particularly in the context of chronic viral challenge and tumor microenvironments [202]. In addition to Ezh2 expression levels, it is important to understand the cellular and viral contexts that regulate terminal effector differentiation, memory cell generation and exhaustion [203]. Thus, the observed function of EZH2 may come to light through pharmacologic inhibition and subsequent analysis of T cell responses [204]. The histone methyltransferase EZH2 represses memory and survival genes, by depositing H3K27me3 at these loci in terminally differentiated effector cells; whereas ectopic deposition of H3K27Ac marks both memory and effector loci in response to subsequent antigen re-encounter in the context of multipotent memory cells [205]. Therefore, depletion of epigenetic machinery such as EZH2 may enhance T-cell development and function to augment both anti-tumor immunity and immunotherapies [206,207]. Thus, understanding how fibroblasts and other stromal cells modulate T cell epigenetics in chronic infection and cancer models could uncover novel therapeutic targets [208]. This requires the integration of epigenomics, transcriptomics and

metabolomics data to understand complex regulatory networks directing T cell fate decisions [209].

In particular, identifying the various histone deacetylases or demethylases responsible for establishing and maintaining these epigenetic changes and their functional relevance in context must ongoing studies to target T cell exhaustion [203]. EZH2 inhibition increases TCF1 expression, memory-associated gene loci, and CCR7+CD62L+CD8+ T cell percentage (indicators of memory T-cell potential) by decreasing the repressive histone mark H3K27me3 [210,211]. EZH2 inhibition can encourage a memory-like phenotype of CD8T cells through the upregulation of TCF1 and the downregulation of exhaustion-associated genes, highlighting its importance as an epigenetic regulator in programming CD8+ T cell fate [204]. Reduction of transient EZH2 enhances T cell stemness and polyfunctionality in CAR104 [212,213]. Inhibitors of EZH2, especially tazemetostat, can induce a memory-like phenotype in T cells characterized by higher expression CD62L and TCF-1 and lower expression of inhibitory receptors PD-1, LAG-3, Tim-3 also allowing the maintained cell proliferation [214]. Lowered H3K27 methylation induces an epigenetic change that specifically enhances TCF1, a transcription factor associated with T cell self-renewal [215,216]. This mechanistic insight into the function of EZH2 in T cell fate determination provided opportunities for epigenetic strategies to enhance immune-inhibitory therapies. T cell dysfunction in patients is marked by metabolic insufficiency and changes in epigenetic profiles [217], so an interesting aspect for future work might be to explore how cancer methionine signaling targets the same functional T cell pathways that may be reprogrammed.epigenetically.³⁷³⁹ Whether glucose-based inhibition of SLC43A2 levels could effectively normalize T cell metabolism while simultaneously providing a synergistic boost to EZH2 inhibition's epigenetic reprogramming, remains another unanswered question.

Future studies should address how long-lived antigen persistence, cytokine signals, inhibitory receptors, stromal cell interactions and metabolic cues control the destiny of activated cellular traits towards either memory or exhausted phenotypes over time. Targeting epigenetic regulators such as EZH2 may impact T cell memory, depleted T cell function and vaccine or immunotherapy outcomes. There is a potential for further research in this field. It identifies molecular and epigenetic targets that might enhance immunological memory and therapy. The discussion is limited to viral infections and

durability of responses because some sections centre around cancer immunotherapy. Linking these systems back to chronic virus infections would enhance paper coherence. This study demonstrates that immunological memory is an exquisitely orchestrated and prolonged immune response against viral infections. Humoral immunity, which mediates antibodies, memory B cells and long-lived plasma cells, combined with cellular immunity - CD4 helper T cells; CD8 cytotoxic T cell; tissue-resident memory T cell (Trm) and T follicular helper (Tfh) cells act in protection. The breadth of this memory reaction and how long it lasts is dictated by germinal centre reactions, cytokine signaling, antigen persistence, the host's state of immunological readiness, transcriptional regulation and epigenetic programming.

The key point that I think this paper is making, in particular, is that you can't measure levels of antibodies and just be able to gauge protective antiviral immunity. Rather, this is a protective immunological network that consists of antibodies and T cells: exquisitely complex. T cells may be exhausted from recurrent viral infections, leading to less protective memory. Identification of TCF-1⁺ progenitor fatigued T cells ends up being a potential target. In conclusion, future vaccine and immune-based therapies need to induce long-lasting, broad, adaptable and functionally competent memory responses that potentiate a strong defense against recurrent, chronic and novel viral infections.

Conclusions:

1. Immunological Memory Is Important for Long-term Protection: Long-term protection against viral infections relies on immunological memory, which includes memory B cells, antibodies, CD4⁺ T cells, CD8⁺ T cells and T follicular helper (Tfh) cells. Humoral and cellular immunity are complicated processes that allow a memory of previous infections which can result in an instantaneous reaction.
2. Factors determining how long immune memory lasts: type of virus, persistence of antigen, germinal center response quality, cytokine environment and host characteristics including age and immunological status While some immune responses persist for a long time, others can fade away gradually.
3. T Cell Depletion in Long-Term Infections: A prolonged viral infection itself could lead to a phenomenon termed T cell exhaustion that may limit the efficacy

of immune memory. TCF-1⁺ progenitor T cells could be under pressure of attrition but are still able to self-renew—possibly maintaining homeostatic control of the immune system during chronic viral infections.

Recommendations for Future Research and Applications:

1. Focus on Cellular and Host Immunity: Future vaccine and therapeutic development efforts should extend beyond simply focusing on antibody production. For reliable and long-lasting protection against viral infections, we need to focus on stimulating both arms of our immune defenses: humoral immunity (mediated by antibodies) and cellular immunity (mediated by T cells).
2. Mechanisms of Targeted T Cell Depletion: The mechanisms underlying T cell depletion in cancers and chronic infections require further investigation. Therefore, targets for immune reprogramming to achieve long-lasting immunity should be identified, including stem cell-like markers such as TCF-1.
3. Long-Lasting Vaccines Targeting Functional Memory T Cells, Long-Term Memory B Cells, and Plasma Cells. To enhance immune memory and prevent depletion, we need to pay more attention to epigenetic regulation.
4. Patient-Specific Cancer Immunology Strategies: Each person's immune system is unique and responds differently to vaccinations and diseases. It is important to develop more personalized vaccine strategies based on patient age, genetic background, and immunological status. Gaining this knowledge is essential for creating more effective vaccines, since age, immunosuppression, and previous infections can affect the formation of immune memory against pathogens.
5. Epigenetic and Transcriptional Regulation of Memory Cells: Finally, further investigation is needed into the epigenetic pathways that determine the lifespan and function of memory cells. Novel strategies to enhance vaccine response and immune memory may be possible by targeting specific epigenetic regulators such as EZH2 and TCF-1.
6. Utilizing Circulating Tfh Cell Biomarkers: Activation of the adaptive immune system, antibody production, and longevity can be reflected in circulating follicular helper T (Tfh) cells (17-19). Further studies of these cells may provide more useful alternative indicators of germline activity and antibody

persistence, which could help guide the development of improved vaccine formulations.

7. Improving our understanding of plasma cell and B memory cell dynamics: A better understanding of plasma cell and B memory cell dynamics is essential for developing more effective vaccines. This is especially true for rapidly evolving viral infections. Future research may help clarify the role of these cells in immunity against novel strains of endemic viruses, such as SARS-CoV-2.
8. Focusing on long-term viral infections: Future studies should incorporate an element of immunological memory into long-term follow-up, focusing on learning from chronic conditions and holistic simulations (e.g., HIV/AIDS, hepatitis C, and chronic influenza). Identifying novel therapies that preserve immune function during these infections could lead to better treatment for patients with persistent viral illnesses.

Research Novelty and Gap:

Research Novelty:

1. Comprehensive Assessment of Immune Memory: This research contributes to our understanding of antiviral immunity by examining humoral and cellular (T and B cell) immune responses, focusing on the roles of both antibody-dependent and cellular mechanisms. Unlike other studies, the underlying hypothesis explaining the persistence of long-term immunity in this study is not based on a single mechanism, but rather emphasizes the complex interaction between memory B cells and CD4⁺ and CD8⁺ T cells (Tfh) within cytokine networks.
2. Focus on T Cell and T-Receptor Fatigue: One of the attractive aspects of this study is its innovative focus on exploring the importance of T cells depleted of TCF-1⁺ precursors, with detailed analyses of T cell fatigue in chronic viral infections. These T cells may offer valuable insights into immune reprogramming strategies for restoring activity after prolonged exposure to viral antigens, potentially aiding in the regeneration of depleted T cells. This emerging field of immunology research holds significant potential for treating cancer and chronic infections through immunotherapy.
3. The Role of Cytokines and Epigenetics in Memory Mechanisms: This research addresses another emerging question: how cytokine signaling contributes to the

epigenetic control of memory cell development and persistence. The findings link the maintenance of memory B cells, T cells, and Tfh cells to cytokines (IL-4 and IL-21) and transcription factors such as TCF-1. Therefore, a promising new direction for the future of vaccinations and the design of other immunotherapies lies in investigating how to modulate the epigenetic mechanisms of long-term immunity, particularly between T cells and memory B cells. This area remains largely unexplored.

4. Using circulating Tfh cells as biomarkers: Based on this study, we propose the following conceptual model: Follicular helper T (Tfh) cells appearing in the bloodstream may constitute realistic alternative measures of germinal center activity and vaccine efficacy duration. This gives us a realistic ability to measure the immune response in near real-time, which can be used as a guide for personalized immunization strategies.

Research Gap:

1. Unknown Aspects of Memory Cell Heterogeneity: Studies indicate significant differences in viewpoints regarding functional differences among Tfh cell subsets, T and B memory cell subsets, antigen specialization within T and B memory cell subsets, and differences in infection history across various parts of the immune system. This study summarizes the function of these cells; however, available data are very limited regarding the phenotypic and functional differences among Tfh subsets (e.g., Tfh1, Tfh2, and Tfh17) and their impact on immunity. This warrants further in-depth studies to determine their individual roles in memory persistence and quality across diverse populations with varying demographic characteristics.
2. Limited Understanding of Memory Cell Epigenetics and Function: Although this study highlights the importance of epigenetic regulation in immune memory, a precise understanding of how epigenetic modifications (e.g., DNA methylation and histone modifications) regulate memory cell formation and function in response to various viral infections remains lacking. Future studies should seek to identify specific epigenetic signatures that regulate the persistence of T and B memory cells, particularly in the context of long-term viral infections, including HIV/AIDS and hepatitis C.

3. Immunological memory can be compromised when T cells get fatigued from chronic infections, but the underlying mechanisms are still not fully understood. Nonetheless, it is poorly understood how these exhausted T cells like the progenitor T cell of TCF-1⁺ can still sustain immune function. More targeted investigations that will reveal the molecular circuits and epigenetic mechanisms governing T cell depletion are required in order to re-establish durable immunity in chronic infections.
4. Main Limitations: Disparity in Clinical Significance Between Age Groups and Immunocompromised Participants: We have no data on how aging, immunosuppression or other chronic co-morbidities may affect the durability of immunological memory, since our study is limited to addressing certain factors that render memory cells durable. The influence of these features on immunological responses to vaccines and to viral challenges, especially in immunocompromised patients, the elderly and those with autoimmune disorders are mostly unknown. Improved vaccination strategies targeting specific populations need the additional clinical trials with these groups.
5. Underappreciated Roles of Non-Immune Cells in Maintaining Immune Memory: Although immune cells are the main focus of discussion, much remains unknown about the contribution of non-immune cells (such as chondrocytes and fibroblasts) to maintaining immune memory. These cells may influence the fate of memory cells either through cytokine production or through tissue remodeling. Future studies should also focus on how these non-immune cells influence the growth and maintenance of memory B cells and memory T cells after acute and chronic infections.
6. This study contributes to our understanding of the biological mechanisms underlying immune memory by investigating the role of epigenetic regulation and T cell exhaustion, as well as the interactions between humoral and cellular immunity. It also introduces a new concept for using circulating Tfh cells as biomarkers of the immune response. The study also addresses the underrepresentation of the impact of chronic diseases on immune responses, the epigenetic influence on memory cells, and the diversity gaps in peripheral naïve immune cells.
7. The study also explores the underrepresentation of the impact of chronic diseases on immune responses, the epigenetic influence on memory cells, and

the diversity gaps in peripheral naïve immune cells. 7. Further research is needed to understand and treat both acute and chronic viral infections, as well as to design effective vaccines and treatments based on the observations outlined in this work.

References

1. Das A, Pathak S, Premkumar M, Sarpparajan CV, Balaji E, Duttaroy AK, et al. A brief overview of SARS-CoV-2 infection and its management strategies: a recent update. *Molecular and Cellular Biochemistry*. Springer Science+Business Media; 2023 Sept 24;479(9):2195–215. <https://doi.org/10.1007/s11010-023-04848-3>
2. Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. *Immunological Reviews*. 2022 June 22;310(1):27–46. <https://doi.org/10.1111/imr.13089>
3. Radbruch A, Chang H. A long-term perspective on immunity to COVID. Vol. 595, *Nature*. Nature Portfolio;2021. p.359–60. <https://doi.org/10.1038/d41586-021-01557-z>
4. Mistry P, Barmania F, Mellet J, Peta KT, Strydom A, Viljoen IM, et al. SARS-CoV-2 Variants, Vaccines, and Host Immunity. *Frontiers in Immunology*. Frontiers Media; 2022 Jan 3;12:809244–809244. <https://doi.org/10.3389/fimmu.2021.809244>
5. Cromer D, Juno JA, Khoury DS, Reynaldi A, Wheatley AK, Kent SJ, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. *Nature reviews Immunology*. Nature Portfolio; 2021 Apr 29;21(6):395–404. Available from: <https://doi.org/10.1038/s41577-021-00550-x>
6. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell*. 2020 Nov 23;184(1):169. <https://doi.org/10.1016/j.cell.2020.11.029>
7. Kotaki R, Moriyama S, Takahashi Y. Humoral immunity for durable control of SARS-CoV-2 and its variants. *Inflammation and Regeneration*. BioMed Central; 2023 Jan 12;43(1). Available from: <https://doi.org/10.1186/s41232-023-00255-9>
8. Roy RK, Yadav R, Jain A, Tripathi V, Jain M, Singh S, et al. Yin and yang of immunological memory in controlling infections: Overriding self defence mechanisms. *International Reviews of Immunology*. 2021 Apr 19;41(2):240–52. Available from: <https://doi.org/10.1080/08830185.2021.1912037>
9. Moga E, Lynton-Pons E, Domingo P. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. *Frontiers in Immunology*. Frontiers Media; 2022 June 27;13. <https://doi.org/10.3389/fimmu.2022.904686>
10. Upreti S, Samant M. A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. *Pharmaceutical Research*. Springer

Science+Business Media; 2022 July 1;39(9):2119–34. <https://doi.org/10.1007/s11095-022-03323-w>

11. Mahdisoltani S, Murugan P, Chakraborty AK, Kardar M. Minimal framework for optimizing vaccination protocols targeting highly mutable pathogens. *Physical review E*. 2024 Dec 19;110(6). Available from: <https://doi.org/10.1103/physreve.110.064137>
12. Chen Y, Tong P, Whiteman NB, Moghaddam AS, Zarghami M, Zuiani A, et al. Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. *Science Immunology*. 2022 May 12;7(78). <https://doi.org/10.1126/sciimmunol.abp8328>
13. Pepper M, Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. 2020 Aug 13; Available from: <https://doi.org/10.21203/rs.3.rs-57112/v1>
14. Laidlaw BJ, Ellebedy AH. The germinal centre B cell response to SARS-CoV-2. *Nature reviews Immunology. Nature Portfolio*; 2021 Dec 6;22(1):7–18. Available from: <https://doi.org/10.1038/s41577-021-00657-1>
15. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. *The Journal of Immunology*. 2021 May 1;206. Available from: <https://doi.org/10.4049/jimmunol.206.suppl.62.06>
16. Muecksch F, Wang Z, Cho A, Gaebler C, Tanfous TB, DaSilva J, et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. *Nature*. 2022 Apr 21;607(7917):128–34. <https://doi.org/10.1038/s41586-022-04778-y>
17. Aguilar-Bretones M, Fouchier RAM, Koopmans M, Nierop GP van. Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. *Journal of Clinical Investigation. American Society for Clinical Investigation*; 2023 Jan 2;133(1). Available from: <https://doi.org/10.1172/jci162192>
18. Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F, et al. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. *JCI Insight*. 2022 Nov 15;7(24). <https://doi.org/10.1172/jci.insight.163471>
19. Torres-Flores A, Wong-Baeza I, López-Macías C. Contribution of memory T cells to the generation of long-lasting immunity against COVID-19. *Gaceta Médica de México. Academia Nacional de Medicina de México*; 2024 Aug 6;160(2). Available from: <https://doi.org/10.24875/gmm.m24000878>
20. Zhou Z, Li D, Zhao Z, Shi S, Wu J, Li J, et al. Dynamical modelling of viral infection and cooperative immune protection in COVID-19 patients. *PLoS Computational Biology*. 2023 Sept 1;19(9). <https://doi.org/10.1371/journal.pcbi.1011383>
21. Pons S, Uhel F, Frapy E, Séréme Y, Zafrani L, Aschard H, et al. How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response? *Stem Cell*

- Reviews and Reports. Springer Nature; 2022 Nov 24;19(3):585–600. Available from: <https://doi.org/10.1007/s12015-022-10477-y>
22. Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. *GeroScience*. Springer International Publishing; 2020 Apr 1;42(2):505–14. <https://doi.org/10.1007/s11357-020-00186-0>
 23. Son YM, Cheon IS, Wu Y, Li C, Wang Z, Gao X, et al. Tissue-resident CD4 + T helper cells assist the development of protective respiratory B and CD8 + T cell memory responses. *Science Immunology*. 2021 Jan 8;6(55). <https://doi.org/10.1126/sciimmunol.abb6852>
 24. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. *The Journal of Experimental Medicine*. 2020 Apr 30;217(6). <https://doi.org/10.1084/jem.20200678>
 25. Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. *Signal Transduction and Targeted Therapy*. Springer Nature; 2023 June 19;8(1). <https://doi.org/10.1038/s41392-023-01471-y>
 26. Sekaran SD, Ismail AA, Thergarajan G, Chandramathi S, Rahman S, Mani RR, et al. Host immune response against DENV and ZIKV infections. *Frontiers in Cellular and Infection Microbiology*. Frontiers Media; 2022 Sept 8;12. <https://doi.org/10.3389/fcimb.2022.975222>
 27. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. *Nature reviews Immunology*. Nature Portfolio; 2020 Sept 4;20(10):615–32. <https://doi.org/10.1038/s41577-020-00434-6>
 28. Li M, Wang H, Tian L li, Pang Z, Yang Q, Huang T, et al. COVID-19 vaccine development: milestones, lessons and prospects. *Signal Transduction and Targeted Therapy*. Springer Nature; 2022 May 3;7(1):146–146. <https://doi.org/10.1038/s41392-022-00996-y>
 29. Shah VK, Fimal P, Alam A, Ganguly D, Chattopadhyay S. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. *Frontiers in Immunology*. Frontiers Media; 2020 Aug 7;11. <https://doi.org/10.3389/fimmu.2020.01949>
 30. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. *Nature reviews Immunology*. Nature Portfolio; 2021 July 1;21(8):475–84. <https://doi.org/10.1038/s41577-021-00578-z>
 31. Frank K, Paust S. Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection. *Frontiers in Cellular and Infection Microbiology*. Frontiers Media; 2020 Aug 18;10. Available from: <https://doi.org/10.3389/fcimb.2020.00425>

32. Wang Y, Tian Q, Ye L. The Differentiation and Maintenance of SARS-CoV-2-Specific Follicular Helper T Cells. *Frontiers in Cellular and Infection Microbiology*. Frontiers Media; 2022 July 14;12. <https://doi.org/10.3389/fcimb.2022.953022>
33. Yasamineh S, Kalajahi HG, Yasamineh P, Gholizadeh O, Youshanlouei HR, Matloub SK, et al. Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19. *Stem Cell Research & Therapy*. BioMed Central; 2022 June 17;13(1). <https://doi.org/10.1186/s13287-022-02944-7>
34. Lim EY, Jackson S, Wills MR. The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People. *Frontiers in Cellular and Infection Microbiology*. Frontiers Media; 2020 May 19;10. <https://doi.org/10.3389/fcimb.2020.00202>
35. Verma A, Manojkumar A, Dhasmana A, Tripathi M, Jaggi M, Chauhan SC, et al. Recurring SARS-CoV-2 variants: an update on post-pandemic, co-infections and immune response. *Nanotheranostics*. Ivyspring International Publisher; 2024 Jan 1;8(2):247–69. <https://doi.org/10.7150/ntno.91910>
36. Mohammed RN, Tamjidifar R, Rahman HS, Adili A, Ghoreishizadeh S, Saeedi H, et al. A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19). *Cell Communication and Signaling*. BioMed Central; 2022 June 2;20(1). <https://doi.org/10.1186/s12964-022-00856-w>
37. Almendro-Vázquez P, Laguna-Goya R, Paz-Artal E. Defending against SARS-CoV-2: The T cell perspective. *Frontiers in Immunology*. Frontiers Media; 2023 Jan 27;14. <https://doi.org/10.3389/fimmu.2023.1107803>
38. Ma S, Ming Y, Wu J, Cui G. Cellular metabolism regulates the differentiation and function of T-cell subsets. *Cellular and Molecular Immunology*. Springer Nature; 2024 Apr 2;21(5):419–35. <https://doi.org/10.1038/s41423-024-01148-8>
39. Nowill AE, Caruso M, Campos-Lima PO de. T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets. *Frontiers in Immunology*. Frontiers Media; 2023 June 14;14. <https://doi.org/10.3389/fimmu.2023.1133225>
40. Breton G, Mendoza P, Häggglöf T, Oliveira TY, Schaefer-Babajew D, Gaebler C, et al. Persistent cellular immunity to SARS-CoV-2 infection. *The Journal of Experimental Medicine*. 2021 Jan 27;218(4). <https://doi.org/10.1084/jem.20202515>
41. Li L, Müftüoğlu M, Liang S, Basyal M, Lv J, Akdogan ME, et al. In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. *JCI Insight*. 2022 Mar 1;7(7). <https://doi.org/10.1172/jci.insight.156559>
42. Phetsouphanh C, Khoo WH, Jackson K, Klemm V, Howe A, Aggarwal A, et al. High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells. *Frontiers in Immunology*. 2022 Dec 5;13. <https://doi.org/10.3389/fimmu.2022.1032911>

43. Ahmad T, Chaudhuri RK, Joshi MC, Almatroudi A, Rahmani AH, Syed MA. COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. *Frontiers in Microbiology*. *Frontiers Media*; 2020 Dec 1;11. <https://doi.org/10.3389/fmicb.2020.588409>
44. Menges D, Zens KD, Ballouz T, Caduff N, Llanas-Cornejo D, Aschmann HE, et al. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. *Nature Communications*. 2022 Aug 18;13(1). Available from: <https://doi.org/10.1038/s41467-022-32573-w>
45. Menges D, Zens KD, Ballouz T, Caduff N, Llanas-Cornejo D, Aschmann HE, et al. Heterogenous Cellular and Humoral Immune Trajectories after SARS-CoV-2 Infection: Compensatory Responses in a Population-Based Cohort. *medRxiv (Cold Spring Harbor Laboratory)*. 2021 Dec 16; <https://doi.org/10.1101/2021.12.15.21267776>
46. Miyazawa M. Immunopathogenesis of SARS-CoV-2-induced pneumonia: lessons from influenza virus infection. *Inflammation and Regeneration*. *BioMed Central*; 2020 Oct 12;40(1). Available from: <https://doi.org/10.1186/s41232-020-00148-1>
47. Brasu N, Elia I, Russo V, Montacchiesi G, Stabile SA, Intinis CD, et al. Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination. *Nature Immunology*. 2022 Sept 22;23(10):1445–56. Available from: <https://doi.org/10.1038/s41590-022-01313-z>
48. Tian Y, Carpp LN, Miller HER, Zager M, Newell EW, Gottardo R. Single-cell immunology of SARS-CoV-2 infection. *Nature Biotechnology*. *Nature Portfolio*; 2021 Dec 20;40(1):30–41. <https://doi.org/10.1038/s41587-021-01131-y>
49. Qi F, Cao Y, Zhang S, Zhang Z. Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination. *Frontiers in Immunology*. *Frontiers Media*; 2022 Sept 2;13. <https://doi.org/10.3389/fimmu.2022.964976>
50. Lapuente D, Winkler T, Tenbusch M. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. *Cellular and Molecular Immunology*. *Springer Nature*; 2023 Nov 10;21(2):144–58. Available from: <https://doi.org/10.1038/s41423-023-01095-w>
51. Ackermann-Gäumann R, Lang P, Zens KD. Defining the “Correlate(s) of Protection” to tick-borne encephalitis vaccination and infection – key points and outstanding questions. *Frontiers in Immunology*. 2024 Jan 22;15. <https://doi.org/10.3389/fimmu.2024.1352720>
52. Netea MG, Li Y. Immune memory in individuals with COVID-19. *Nature Cell Biology*. 2021 June 1;23(6):582–4. <https://doi.org/10.1038/s41556-021-00689-8>
53. Jeffery-Smith A, Burton AR, Lens S, Rees-Spear C, Davies J, Patel M, et al. SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable

neutralizing antibodies. *Journal of Clinical Investigation*. 2021 Nov 29;132(2). Available from: <https://doi.org/10.1172/jci152042>

54. Gu Y, Shunmuganathan BDO, Qian X, Gupta R, Tan RSW, Kozma M, et al. Employment of a high throughput functional assay to define the critical factors that influence vaccine induced cross-variant neutralizing antibodies for SARS-CoV-2. *Scientific Reports*. 2023 Dec 9 ;13(1). <https://doi.org/10.1038/s41598-023-49231-w>
55. Ripperger TJ, Bhattacharya D. Transcriptional and Metabolic Control of Memory B Cells and Plasma Cells. *Annual Review of Immunology* [Internet]. 2021 Feb 9;39(1):345–68. <https://doi.org/10.1146/annurev-immunol-093019-125603>
56. Odak I, Förster R, Bošnjak B. Hide and seek with SARS-CoV-2: spike receptor-binding domain-specific memory B cells still recognize Omicron variant. Vol. 7, *Signal Transduction and Targeted Therapy*. Springer Nature; 2022. Available from: <https://doi.org/10.1038/s41392-022-01192-8>
57. Syeda MZ, Tu H, Huang C, Huang W, Mu Q. B cell memory: from generation to reactivation: a multipronged defense wall against pathogens. *Cell Death Discovery*. 2024 Mar 7;10(1). Available from: <https://doi.org/10.1038/s41420-024-01889-5>
58. Nishio A, Hasan S, Park H, Park N, Salas J, Salinas E, et al. Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C. *Nature Communications*. 2022 Sept 16;13(1). <https://doi.org/10.1038/s41467-022-33035-z>
59. Kealy L, Good-Jacobson KL. Advances in understanding the formation and fate of B-cell memory in response to immunization or infection. *Oxford Open Immunology*. 2021 Jan 1;2(1). Available from: <https://doi.org/10.1093/oxfimm/iqab018>
60. Fryer HA, Hartley GE, Edwards ESJ, O'Hehir RE, Zelm MC van. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. *Biochemical Society Transactions*. 2022 Nov 24;50(6):1643–58. Available from: <https://doi.org/10.1042/bst20220415>
61. Zurbuchen Y, Michler J, Taeschler P, Adamo S, Cervia C, Raeber ME, et al. Human memory B cells show plasticity and adopt multiple fates upon recall response to SARS-CoV-2. *Nature Immunology*. 2023 Apr 27;24(6):955–65. Available from: <https://doi.org/10.1038/s41590-023-01497-y>
62. Podestà MA, Cavazzoni CB, Hanson BL, Bechu ED, Ralli G, Clement RL, et al. Stepwise differentiation of follicular helper T cells reveals distinct developmental and functional states. *Nature Communications*. 2023 Nov 24;14(1). Available from: <https://doi.org/10.1038/s41467-023-43427-4>
63. Foster WS, Lee JL, Thakur N, Newman J, Spencer AJ, Davies S, et al. Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination. *Cell Reports Medicine*. 2022 Nov 16;3(12):100845–100845. <https://doi.org/10.1016/j.xcrm.2022.100845>

64. Choi J, Crotty S, Choi YS. Cytokines in Follicular Helper T Cell Biology in Physiologic and Pathologic Conditions. *Immune Network*. 2024 Jan 1;24(1). Available from: <https://doi.org/10.4110/in.2024.24.e8>
65. Boothby M, Brookens SK, Raybuck A, Cho SH. Supplying the trip to antibody production—nutrients, signaling, and the programming of cellular metabolism in the mature B lineage. *Cellular and Molecular Immunology*. Springer Nature; 2021 Nov 15;19(3):352–69. Available from: <https://doi.org/10.1038/s41423-021-00782-w>
66. Szabó K, Jámbo I, Szántó A, Horváth IF, Tarr T, Nakken B, et al. The Imbalance of Circulating Follicular T Helper Cell Subsets in Primary Sjögren's Syndrome Associates With Serological Alterations and Abnormal B-Cell Distribution. *Frontiers in Immunology*. 2021 Mar 19;12. <https://doi.org/10.3389/fimmu.2021.639975>
67. Fu N, Xie F, Sun Z, Wang Q. The OX40/OX40L Axis Regulates T Follicular Helper Cell Differentiation: Implications for Autoimmune Diseases. *Frontiers in Immunology*. Frontiers Media; 2021 June 21;12. <https://doi.org/10.3389/fimmu.2021.670637>
68. Kim YJ, Choi J, Choi YS. Transcriptional regulation of Tfh dynamics and the formation of immunological synapses. *Experimental & Molecular Medicine*. Springer Nature; 2024 June 3;56(6):1365–72. <https://doi.org/10.1038/s12276-024-01254-7>
69. Yu M, Charles A, Cagigi A, Christ W, Österberg B, Falck-Jones S, et al. Delayed generation of functional virus-specific circulating T follicular helper cells correlates with severe COVID-19. *Nature Communications*. 2023 Apr 15;14(1). Available from: <https://doi.org/10.1038/s41467-023-37835-9>
70. Law H, Venturi V, Kelleher AD, Munier CML. Tfh Cells in Health and Immunity: Potential Targets for Systems Biology Approaches to Vaccination. *International Journal of Molecular Sciences*. 2020 Nov 12;21(22):8524–8524. Available from: <https://doi.org/10.3390/ijms21228524>
71. Lau AWY, Turner V, Bourne K, Hermes JR, Chan TD, Brink R. BAFFR controls early memory B cell responses but is dispensable for germinal center function. *The Journal of Experimental Medicine*. 2020 Oct 29;218(2). Available from: <https://doi.org/10.1084/jem.20191167>
72. He R, Zheng X, Zhang J, Liu B, Wang Q, Wu Q, et al. SARS-CoV-2 spike-specific TFH cells exhibit unique responses in infected and vaccinated individuals. *Signal Transduction and Targeted Therapy*. 2023 Oct 6;8(1). Available from: <https://doi.org/10.1038/s41392-023-01650-x>
73. Lakshmanappa YS, Elizaldi SR, Roh JW, Schmidt B, Carroll TD, Weaver KD, et al. SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. *Nature Communications*. 2021 Jan 22;12(1). Available from: <https://doi.org/10.1038/s41467-020-20642-x>
74. Yu M, Charles A, Cagigi A, Christ W, Österberg B, Falck-Jones S, et al. Delayed generation of functional virus-specific circulating T follicular helper cells correlates

with severe COVID-19. medRxiv (Cold Spring Harbor Laboratory). 2022 July 12; Available from: <https://doi.org/10.1101/2022.07.12.22277549>

75. Stavropoulou E, Kantartzi K, Tsigalou C, Konstantinidis T, Voidarou C, Konstantinidis T, et al. Unraveling the Interconnection Patterns Across Lung Microbiome, Respiratory Diseases, and COVID-19. *Frontiers in Cellular and Infection Microbiology*. Frontiers Media; 2021 Jan 28 10. Available from: <https://doi.org/10.3389/fcimb.2020.619075>
76. Priest DG, Ebihara T, Tulyeu J, Søndergaard JN, Sakakibara S, Sugihara F, et al. Atypical and non-classical CD45RBlo memory B cells are the majority of circulating SARS-CoV-2 specific B cells following mRNA vaccination or COVID-19. *Nature Communications*. 2024 Aug 9;15(1). <https://doi.org/10.1038/s41467-024-50997-4>
77. Zhu Q, Xu Y, Wang T, Xie F. Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. *Frontiers in Immunology*. Frontiers Media; 2022 Nov 22;13. Available from: <https://doi.org/10.3389/fimmu.2022.1053437>
78. Izmirly AM, Alturki SO, Alturki SO, Connors J, Haddad EK. Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity. *Frontiers in Immunology*. Frontiers Media; 2020 June 16;11. <https://doi.org/10.3389/fimmu.2020.01055>
79. Galloway DR, Nguyen NX, Li J, Houston N, Gregersen G, Williamson ED, et al. The magnitude of the germinal center B cell and T follicular helper cell response predicts long-lasting antibody titers to plague vaccination. *Frontiers in Immunology*. 2022 Oct 28;13. Available from: <https://doi.org/10.3389/fimmu.2022.1017385>
80. Ioannidou K, Ndiaye DR, Noto A, Fenwick C, Fortis SP, Pantaleo G, et al. In Situ Characterization of Follicular Helper CD4 T Cells Using Multiplexed Imaging. *Frontiers in Immunology*. 2021 Feb 3;11. <https://doi.org/10.3389/fimmu.2020.607626>
81. Khanam A, Ayithan N, Tang L, Poonia B, Kottlil S. IL-21–Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B. *Frontiers in Immunology*. 2021 Jan 28;11. Available from: <https://doi.org/10.3389/fimmu.2020.599648>
82. Noel GR, Fontsa ML, Garaud S, Silva PD, Wind A de, Eynden GGV den, et al. Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. *Journal of Clinical Investigation*. 2021 Aug 19;131(19). Available from: <https://doi.org/10.1172/jci139905>
83. Lu Y, Craft J. T Follicular Regulatory Cells: Choreographers of Productive Germinal Center Responses. *Frontiers in Immunology*. Frontiers Media; 2021 June 10;12. Available from: <https://doi.org/10.3389/fimmu.2021.679909>
84. Nelson AN, Lin WHW, Shivakoti R, Putnam NE, Mangus LM, Adams RJ, et al. Association of persistent wild-type measles virus RNA with long-term humoral immunity in rhesus macaques. *JCI Insight*. 2020 Jan 14;5(3). Available from: <https://doi.org/10.1172/jci.insight.134992>

85. DeGottardi Q, Gates TJ, Yang J, James EA, Malhotra U, Chow I, et al. Ontogeny of different subsets of yellow fever virus-specific circulatory CXCR5+ CD4+ T cells after yellow fever vaccination. *Scientific Reports*. 2020 Sept 24;10(1). Available from: <https://doi.org/10.1038/s41598-020-72610-6>
86. Cashman SB, Swift T, Song HC, Wright A, Ayer A. Characterization of germinal center and circulating T follicular helper cells using both intracellular and surface CITE-seq. *The Journal of Immunology*. 2023 May 1;210. Available from: <https://doi.org/10.4049/jimmunol.210.suppl.250.15>
87. Zhang J, Wu Q, Liu Z, Wang Q, Wu J, Hu Y, et al. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. *Nature Microbiology*. 2020 Nov 16;6(1):51–8. Available from: <https://doi.org/10.1038/s41564-020-00824-5>
88. Subburayalu J. Immune surveillance and humoral immune responses in kidney transplantation – A look back at T follicular helper cells. *Frontiers in Immunology*. Frontiers Media; 2023 July 12;14. <https://doi.org/10.3389/fimmu.2023.1114842>
89. Jiang W, Wong J, Tan H, Kelly HG, Whitney PG, Barr I, et al. Screening and development of monoclonal antibodies for identification of ferret T follicular helper cells. *Scientific Reports*. 2021 Jan 21;11(1). <https://doi.org/10.1038/s41598-021-81389-z>
90. Godot V, Tchérakian C, Gil L, Cervera-Marzal I, Li G, Cheng L, et al. TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice. *PLoS Pathogens*. 2020 Nov 30;16(11). Available from: <https://doi.org/10.1371/journal.ppat.1009025>
91. O'Connor M, Muir R, Chakhtoura M, Fang M, Moysi E, Moir S, et al. A follicular regulatory Innate Lymphoid Cell population impairs interactions between germinal center Tfh and B cells. *Communications Biology*. 2021 May 12;4(1). Available from: <https://doi.org/10.1038/s42003-021-02079-0>
92. Zhao Q, Dai H, Liu X, Jiang H, Liu W, Feng Z, et al. Helper T Cells in Idiopathic Membranous Nephropathy. *Frontiers in Immunology*. Frontiers Media; 2021 May 20;12. Available from: <https://doi.org/10.3389/fimmu.2021.665629>
93. Gao X, Luo K, Wang D, Wei Y, Yao Y, Deng J, et al. T follicular helper 17 (Tfh17) cells are superior for immunological memory maintenance. *eLife*. 2023 Jan 19;12. Available from: <https://doi.org/10.7554/elife.82217>
94. Zhou P, Cao C, Ji T, Zheng T, Dai Y, Liu M, et al. Longitudinal analysis of memory Tfh cells and antibody response following CoronaVac vaccination. *JCI Insight*. 2023 June 29;8(15). Available from: <https://doi.org/10.1172/jci.insight.168437>
95. Caldirola MS, Martínez MP, Bezrodnik L, Zwirner NW, Gaillard MI. Immune Monitoring of Patients With Primary Immune Regulation Disorders Unravels Higher Frequencies of Follicular T Cells With Different Profiles That Associate With

- Alterations in B Cell Subsets. *Frontiers in Immunology*. 2020 Oct 29;11. Available from: <https://doi.org/10.3389/fimmu.2020.576724>
96. Song W, Craft J. T Follicular Helper Cell Heterogeneity. *Annual Review of Immunology*. 2023 Dec 7;42(1):127–52. <https://doi.org/10.1146/annurev-immunol-090222-102834>
 97. Zhu F, McMonigle RJ, Schroeder AR, Xia X, Figge DA, Greer BD, et al. Spatiotemporal resolution of germinal center Tfh cell differentiation and divergence from central memory CD4⁺ T cell fate. *Nature Communications*. 2023 June 17;14(1). Available from: <https://doi.org/10.1038/s41467-023-39299-3>
 98. Gao X, Luo K, Wang D, Wei Y, Yao Y, Deng J, et al. Type 17 Follicular Helper T (Tfh17) Cells are Superior for Memory Maintenance. 2022 July 31; Available from: <https://doi.org/10.1101/2022.07.31.502219>
 99. Chi X, Gu J, Ma X. Characteristics and Roles of T Follicular Helper Cells in SARS-CoV-2 Vaccine Response. *Vaccines*. 2022 Sept 28;10(10):1623–1623. Available from: <https://doi.org/10.3390/vaccines10101623>
 100. Silva-Cayetano A, Fra-Bidó S, Robert PA, Innocentin S, Burton AR, Watson EM, et al. Spatial dysregulation of T follicular helper cells impairs vaccine responses in aging. *Nature Immunology*. 2023 May 22;24(7):1124–37. <https://doi.org/10.1038/s41590-023-01519-9>
 101. Gao X, Luo K, Wang D, Wei Y, Yao Y, Deng J, et al. Author response: T follicular helper 17 (Tfh17) cells are superior for immunological memory maintenance. 2022 Dec 17; <http://dx.doi.org/10.7554/elife.82217.sa2>
 102. Yang Q, Zhang F, Chen H, Hu Y, Yang N, Yang W, et al. The differentiation courses of the Tfh cells: a new perspective on autoimmune disease pathogenesis and treatment. *Bioscience Reports*. Portland Press; 2023 Dec 5;44(1). <https://doi.org/10.1042/bsr20231723>
 103. Salek-Ardakani S, Fousteri G, Cicalese MP. Editorial: Follicular helper T cells in immunity and autoimmunity, volume II. *Frontiers in Immunology*. 2026 Feb 9;17. Available from: <https://doi.org/10.3389/fimmu.2026.1790802>
 104. Murayama K, Ikegami I, Kamekura R, Sakamoto H, Yanagi M, Kamiya S, et al. CD4⁺CD8⁺ T follicular helper cells regulate humoral immunity in chronic inflammatory lesions. *Frontiers in Immunology*. 2022 Aug 25;13. Available from: <https://doi.org/10.3389/fimmu.2022.941385>
 105. Qi J, Liu C, Bai Z, Li X, Yao G. T follicular helper cells and T follicular regulatory cells in autoimmune diseases. *Frontiers in Immunology*. *Frontiers Media*; 2023 Apr 28;14. Available from: <https://doi.org/10.3389/fimmu.2023.1178792>

106. Han F, Zhao Z, Zhao X, Bai X, Fu W, Zheng L, et al. A novel memory-like Tfh cell subset is precursor to effector Tfh cells in recall immune responses. *The Journal of Experimental Medicine*. 2023 Dec 4;221(1). <https://doi.org/10.1084/jem.20221927>
107. Dave S, Ballesteros-Tato A. Noncanonical functions of T follicular helper cells. *Science Immunology*. 2025 June 13;10(108). <https://doi.org/10.1126/sciimmunol.adr1052>
108. Künzli M, Schreiner D, Pereboom TC, Swarnalekha N, Litzler LC, Lötscher J, et al. Long-lived T follicular helper cells retain plasticity and help sustain humoral immunity. *Science Immunology*. 2020 Mar 6;5(45). <https://doi.org/10.1126/sciimmunol.aay5552>
109. Yanagi M, Ikegami I, Kamekura R, Sato T, Sato T, Kamiya S, et al. Bob1 maintains T follicular helper cells for long-term humoral immunity. *Communications Biology*. 2024 Feb 15;7(1). <https://doi.org/10.1038/s42003-024-05827-0>
110. Sheikh AA, Groom JR. Transcription tipping points for T follicular helper cell and T-helper 1 cell fate commitment. *Cellular and Molecular Immunology*. Springer Nature; 2020 Sept 30;18(3):528–38. <https://doi.org/10.1038/s41423-020-00554-y>
111. Yi L, Li Y. Stem-like T cells and niches: Implications in human health and disease. *Frontiers in Immunology*. Frontiers Media; 2022 Aug 17;13. Available from: <https://doi.org/10.3389/fimmu.2022.907172>
112. Krueger PD, Osum KC, Jenkins MK, Krueger PD, Osum KC, Jenkins MK. CD4+ Memory T-Cell Formation during Type 1 Immune Responses. *Cold Spring Harbor Perspectives in Biology*. Cold Spring Harbor Laboratory Press; 2021 Apr 26;13(12). Available from: <https://doi.org/10.1101/cshperspect.a038141>
113. Raynor J, Chapman NM, Chi H. Metabolic Control of Memory T-Cell Generation and Stemness. *Cold Spring Harbor Perspectives in Biology*. Cold Spring Harbor Laboratory Press; 2021 Apr 5;13(6). <https://doi.org/10.1101/cshperspect.a037770>
114. Juno JA, Hill DL. T follicular helper cells and their impact on humoral responses during pathogen and vaccine challenge. *Current Opinion in Immunology*. 2021 Nov 30;74:112–7. Available from: <https://doi.org/10.1016/j.coi.2021.11.004>
115. Govender M, Hopkins FR, Göransson R, Svanberg C, Shankar EM, Hjorth M, et al. T cell perturbations persist for at least 6 months following hospitalization for COVID-19. *Frontiers in Immunology*. 2022 Aug 8;13. Available from: <https://doi.org/10.3389/fimmu.2022.931039>
116. Shukla S, Shukla AK, Ray N, Upadhyay AM, Mirone G, Mongre RK. Long-lasting Response of Human Circulating T-follicular Helper Cells (cTfh) To Post SARS-CoV-2 mRNA Immunization. 2024 Nov 13;7(1):228–46. Available from: <https://doi.org/10.9734/aji/2024/v7i1147>
117. Shen F, Shen Y, Xu Y, Zhao J, Zhao Z, Liu J, et al. Dysregulation of circulating T follicular helper cell subsets and their potential role in the pathogenesis of syphilis.

Frontiers in Immunology. 2023 Oct 12 14. Available from: <https://doi.org/10.3389/fimmu.2023.1264508>

118. Kim C, Jin J, Weyand CM, Goronzy JJ. The Transcription Factor TCF1 in T Cell Differentiation and Aging. International Journal of Molecular Sciences. 2020 Sept 5;21(18):6497–6497. Available from: <https://doi.org/10.3390/ijms21186497>
119. Yermanos A, Sandu I, Pedrioli A, Borsa M, Wagen F, Oetiker N, et al. Profiling Virus-Specific Tcf1+ T Cell Repertoires During Acute and Chronic Viral Infection. Frontiers in Immunology. 2020 May 29;11. <https://doi.org/10.3389/fimmu.2020.00986>
120. Gonzalez NM, Zou D, Gu A, Chen W. Schrödinger's T Cells: Molecular Insights Into Stemness and Exhaustion. Frontiers in Immunology. Frontiers Media; 2021 Aug 26;12. Available from: <https://doi.org/10.3389/fimmu.2021.725618>
121. Rutishauser RL, Deguit CDT, Hiatt J, Blaesche F, Roth TL, Wang L, et al. TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. JCI Insight. 2020 Dec 22;6(3). Available from: <https://doi.org/10.1172/jci.insight.136648>
122. Yermanos A, Sandu I, Pedrioli A, Borsa M, Wagen F, Oetiker N, et al. Profiling virus-specific Tcf1+ T cell repertoires during acute and chronic viral infection. bioRxiv (Cold Spring Harbor Laboratory). 2020 Mar 23; Available from: <https://doi.org/10.1101/2020.03.20.000646>
123. Seo W, Jerin C, Nishikawa H. Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion. Experimental & Molecular Medicine. Springer Nature; 2021 Feb 1;53(2):202–9. <https://doi.org/10.1038/s12276-021-005680>
124. Takata H, Trautmann L. Transforming dysfunctional CD8+ T cells into natural controller-like CD8+ T cells: can TCF-1 be the magic wand?. Vol. 132, Journal of Clinical Investigation. American Society for Clinical Investigation; 2022. Available from: <https://doi.org/10.1172/jci160474>
125. Hofmann M, Jandus C, Lee LN, Utzschneider DT. Editorial: Memory T Cells in Chronic Infections and Tumors. Frontiers in Immunology. 2021 Feb 17;12. Available from: <https://doi.org/10.3389/fimmu.2021.656010>
126. Deak LC, Nicolini V, Hashimoto M, Karagianni M, Schwalie P, Lauener L, et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature. 2022 Sept 28;610(7930):161–72. <https://doi.org/10.1038/s41586-022-05192-0>
127. Busselaar J, Tian S, Eenennaam H van, Borst J. Helpless Priming Sends CD8+ T Cells on the Road to Exhaustion. Frontiers in Immunology. 2020 Oct 6 [;11. Available from: <https://doi.org/10.3389/fimmu.2020.592569>
128. Hu Y, Hudson WH, Kissick H, Medina CB, Baptista AP, Ma C, et al. TGF- β regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection. The Journal of Experimental Medicine. 2022 July 21;219(10). Available from: <https://doi.org/10.1084/jem.20211574>

129. Wen S, Lu H, Wang D, Guo J, Dai W, Wang Z. TCF-1 maintains CD8⁺ T cell stemness in tumor microenvironment. *Journal of Leukocyte Biology*. 2021 May 28;110(3):585–90. Available from: <https://doi.org/10.1002/jlb.5mr1120-778r>
130. Galletti G, Simone GD, Mazza EMC, Puccio S, Mezzanotte C, Bi T, et al. Two subsets of stem-like CD8⁺ memory T cell progenitors with distinct fate commitments in humans. *Nature Immunology*. 2020 Oct 12;21(12):1552–62. Available from: <https://doi.org/10.1038/s41590-020-0791-5>
131. Cai H, Shi J, Yin LB, Zheng JF, Fu Y, Jiang Y, et al. Downregulation of TCF1 in HIV Infection Impairs T-cell Proliferative Capacity by Disrupting Mitochondrial Function. *Frontiers in Microbiology*. 2022 July 6;13. Available from: <https://doi.org/10.3389/fmicb.2022.880873>
132. Na J, Engwerda C. The role of CD4⁺ T cells in visceral leishmaniasis; new and emerging roles for NKG7 and TGFβ. *Frontiers in Cellular and Infection Microbiology*. 2024 May 31;14. <https://doi.org/10.3389/fcimb.2024.1414493>
133. Kanev K, Zehn D. Origin and fine-tuning of effector CD8 T cell subpopulations in chronic infection. *Current Opinion in Virology*. Elsevier BV; 2020 Nov 1;46:27–35. Available from: <https://doi.org/10.1016/j.coviro.2020.10.003>
134. Zhang F, Ding X, Huang H, Jiang H, Jiang J, Zheng X. Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells. *Cancer Biology and Medicine*. 2024 May 31;1–14. <https://doi.org/10.20892/j.issn.2095-3941.2024.0105>
135. Lee J, Lee K, Bae H, Lee K, Lee S, Ma J, et al. IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation. *Frontiers in Immunology*. 2023 June 20;14. <https://doi.org/10.3389/fimmu.2023.1117092>
136. Pichler A, Cannons JL, Schwartzberg PL. The Road Less Taken: Less Appreciated Pathways for Manipulating CD8⁺ T Cell Exhaustion. *Frontiers in Immunology*. Frontiers Media; 2022 July 6;13. <https://doi.org/10.3389/fimmu.2022.926714>
137. Chung HK, McDonald B, Kaech SM. The architectural design of CD8⁺ T cell responses in acute and chronic infection: Parallel structures with divergent fates. *The Journal of Experimental Medicine*. Rockefeller University Press; 2021 Mar 23;218(4). Available from: <https://doi.org/10.1084/jem.20201730>
138. Humblin É, Korpas I, Lu J, Filipescu D, Heide V van der, Goldstein S, et al. Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1 + PD-1 + CD8 T cells. *Science Immunology*. 2023 Aug 4;8(86). Available from: <https://doi.org/10.1126/sciimmunol.adg0878>
139. Chi X, Luo S, Ye P, Hwang W, Cha J, Yan X, et al. T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications. *Frontiers in Immunology*. Frontiers Media; 2023 Feb 20;14. Available from: <https://doi.org/10.3389/fimmu.2023.1104771>

140. Ma C, Zhang N. Lymphoid tissue residency: A key to understand Tcf-1+PD-1+ T cells. *Frontiers in Immunology*. Frontiers Media; 2022 Dec 7;13. Available from: <https://doi.org/10.3389/fimmu.2022.1074698>
141. Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q, et al. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. *Frontiers in Immunology*. Frontiers Media; 2021 Feb 2;11. Available from: <https://doi.org/10.3389/fimmu.2020.622509>
142. Chen Y, Xu Z, Sun H, Ouyang X, Han Y, Yu H, et al. Regulation of CD8+ T memory and exhaustion by the mTOR signals. *Cellular and Molecular Immunology*. Springer Nature; 2023 Aug 15;20(9):1023–39. <https://doi.org/10.1038/s41423-023-01064-3>
143. Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knöpper K, et al. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. *Nature*. 2022 Aug 17;609(7926):354–60. <https://doi.org/10.1038/s41586-022-05105-1>
144. Bulliard Y, Andersson BS, Baysal MA, Damiano JS, Tsimberidou AM. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. *Journal of Hematology & Oncology*. BioMed Central; 2023 Oct 25;16(1). Available from: <https://doi.org/10.1186/s13045-023-01504-7>
145. Ni L. Potential mechanisms of cancer stem-like progenitor T-cell bio-behaviours. *Clinical and Translational Medicine*. 2024 Aug 1;14(8). Available from: <https://doi.org/10.1002/ctm2.1817>
146. Zhang J, Lei F, Tan H. The development of CD8 T-cell exhaustion heterogeneity and the therapeutic potentials in cancer. *Frontiers in Immunology*. Frontiers Media; 2023 May 18;14<https://doi.org/10.3389/fimmu.2023.1166128>
147. Tian W, Qin G, Jia M, Li W, WEI-LI C, Wang H, et al. Hierarchical transcriptional network governing heterogeneous T cell exhaustion and its implications for immune checkpoint blockade. *Frontiers in Immunology*. Frontiers Media; 2023 June 16;14. <https://doi.org/10.3389/fimmu.2023.1198551>
148. Dolina JS, Budimir N, Thomas GD, Salek-Ardakani S. CD8+ T Cell Exhaustion in Cancer. *Frontiers in Immunology*. Frontiers Media; 2021 July 20;12. Available from: <https://doi.org/10.3389/fimmu.2021.715234>
149. Cai C, Samir J, Pirozyan MR, Adikari T, Gupta M, Leung P, et al. Identification of human progenitors of exhausted CD8+ T cells associated with elevated IFN- γ response in early phase of viral infection. *Nature Communications*. 2022 Dec 7;13(1). Available from: <https://doi.org/10.1038/s41467-022-35281-7>
150. Menezes MN de, Chen AXY, Kulkarni N, Sampurno S, Saw NYL, Yap KM, et al. High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion. *Nature Communications*. 2026 Feb 17; Available from: <https://doi.org/10.1038/s41467-026-69671-y>

151. Pagé N, Lemeille S, Vincenti I, Klimek B, Mariotte A, Wagner I, et al. Persistence of self-reactive CD8+ T cells in the CNS requires TOX-dependent chromatin remodeling. *Nature Communications*. 2021 Feb 12;12(1). <https://doi.org/10.1038/s41467-021-21109-3>
152. Li C, Yuan Y, Jiang X, Wang Q. Epigenetic regulation of CD8+ T cell exhaustion: recent advances and update. *Frontiers in Immunology*. 2025 Oct 21;16. Available from: <https://doi.org/10.3389/fimmu.2025.1700039>
153. Blake MK, O'Connell PM, Aldhamen YA. Fundamentals to therapeutics: Epigenetic modulation of CD8+ T Cell exhaustion in the tumor microenvironment. *Frontiers in Cell and Developmental Biology*. *Frontiers Media*; 2023 Jan 4;10. Available from: <https://doi.org/10.3389/fcell.2022.1082195>
154. Koh C, Lee S, Kwak M, Kim B, Chung Y. CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. *Experimental & Molecular Medicine*. *Springer Nature*; 2023 Nov 1;55(11):2287–99. <https://doi.org/10.1038/s12276-023-01105-x>
155. Schnell A, Bod L, Madi A, Kuchroo VK. The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. *Cell Research*. *Springer Nature*; 2020 Jan 23;30(4):285–99. <https://doi.org/10.1038/s41422-020-0277-x>
156. Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T Cell Dysfunction and Exhaustion in Cancer. *Frontiers in Cell and Developmental Biology*. *Frontiers Media*; 2020 Feb 11;8. Available from: <https://doi.org/10.3389/fcell.2020.00017>
157. Neubert EN, DeRogatis JM, Lewis SA, Viramontes KM, Ortega P, Henriquez ML, et al. HMGB2 regulates the differentiation and stemness of exhausted CD8+ T cells during chronic viral infection and cancer. *Nature Communications*. 2023 Sept 13;14(1). Available from: <https://doi.org/10.1038/s41467-023-41352-0>
158. Wagle MV, Vervoort SJ, Kelly MJ, Byl WVD, Peters TJ, Martin BP, et al. Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance. *Nature Communications*. 2021 May 13;12(1). <https://doi.org/10.1038/s41467-021-23044-9>
159. Lacher S, Dörr J, Almeida GP de, Hönninger J, Bayerl F, Hirschberger A, et al. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. *Nature*. 2024 Apr 24;629(8011):417–25. <https://doi.org/10.1038/s41586-024-07254-x>
160. Manna MPL, Azgomi MS, Tamburini B, Badami GD, Mohammadnezhad L, Dieli F, et al. Phenotypic and Immunometabolic Aspects on Stem Cell Memory and Resident Memory CD8+ T Cells. *Frontiers in Immunology*. *Frontiers Media*; 2022 June 17;13. Available from: <https://doi.org/10.3389/fimmu.2022.884148>
161. Rudloff M, Zumbo P, Favret NR, Roetman JJ, Román CRD, Erwin MM, et al. Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division. *Nature Immunology*. 2023 Aug 3;24(9):1527–39. Available from: <https://doi.org/10.1038/s41590-023-01578-y>

162. Chen C, Liu J, Chen Y, Lin A, Mou W, Zhu L, et al. Application of ATAC-seq in tumor-specific T cell exhaustion. *Cancer Gene Therapy*. Springer Nature; 2022 July 6;30(1):1–10. Available from: <https://doi.org/10.1038/s41417-022-00495-w>
163. Zeng Z, Feng W, Ren X. Exhausted T cells and epigenetic status. *Cancer Biology and Medicine*. 2020 Jan 1;17(4):923–36. <https://doi.org/10.20892/j.issn.2095-3941.2020.0338>
164. Li Y, Han M, Wei H, Huang W, Chen Z, Zhang T, et al. Id2 epigenetically controls CD8⁺ T-cell exhaustion by disrupting the assembly of the Tcf3-LSD1 complex. *Cellular and Molecular Immunology*. 2024 Jan 29;21(3):292–308. Available from: <https://doi.org/10.1038/s41423-023-01118-6>
165. Li X, Li Y, Dong L, Chang YX, Zhang X, Wang C, et al. Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8⁺ progenitor exhausted T cell expansion in tumor models. *Journal of Clinical Investigation*. 2023 Feb 28;133(7). Available from: <https://doi.org/10.1172/jci165673>
166. Liu S, Sun Q, Ren X. Novel strategies for cancer immunotherapy: counter-immunoediting therapy. *Journal of Hematology & Oncology*. BioMed Central; 2023 Apr 13;16(1). Available from: <https://doi.org/10.1186/s13045-023-01430-8>
167. Ding J, Yang K, Zhou H, Huang YF, Li H, Zong Z. Landscapes and mechanisms of CD8⁺ T cell exhaustion in gastrointestinal cancer. *Frontiers in Immunology*. Frontiers Media; 2023 Apr 25;14. <https://doi.org/10.3389/fimmu.2023.1149622>
168. Tien F, Lu H, Lin S, Tsai HC. Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. *Journal of Biomedical Science*. BioMed Central; 2023 Jan 10;30(1). <https://doi.org/10.1186/s12929-022-00893-0>
169. Liu Y, Debo B, Li M, Shi Z, Sheng W, Shi Y. LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade. *Nature Communications*. 2021 Nov 24 12(1). Available from: <https://doi.org/10.1038/s41467-021-27179-7>
170. Lamplugh ZL, Fan Y. Vascular Microenvironment, Tumor Immunity and Immunotherapy. *Frontiers in Immunology*. Frontiers Media; 2021 Dec 20;12. Available from: <https://doi.org/10.3389/fimmu.2021.811485>
171. Gao Z, Feng Y, Xu J, Liang J. T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy. *Frontiers in Immunology*. Frontiers Media; 2022 Sept 23;13. <https://doi.org/10.3389/fimmu.2022.977394>
172. Chen-Camaño R, DeAntonio R, López-Vergès S. T-cell exhaustion in COVID-19: what do we know? *Frontiers in Immunology*. 2025 Oct 29;16. Available from: <https://doi.org/10.3389/fimmu.2025.1678149>
173. Immune Responses to Persistent or Recurrent Antigens: Implications for Immunological Memory and Immunotherapy. *Frontiers research topics*. Frontiers Media; 2021. Available from: <https://doi.org/10.3389/978-2-88966-718-5>

174. Viganó S, Bobisse S, Coukos G, Perreau M, Harari A. Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure. *Frontiers in Immunology*. Frontiers Media; 2020 June 30;11. <https://doi.org/10.3389/fimmu.2020.01350>
175. Wang B, Yin H, Zhang Y, Zhao Q, Wang H, Wei J, et al. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms. *Cell & Bioscience*. BioMed Central; 2023 June 30;13(1). Available from: <https://doi.org/10.1186/s13578-023-01073-9>
176. Martin G, Sen DR, Pace M, Robinson N, Meyerowitz J, Adland E, et al. Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy. *Frontiers in Immunology*. 2021 June 4 [cited 2025 Sept];12. Available from: <https://doi.org/10.3389/fimmu.2021.647688>
177. Pace L. Temporal and Epigenetic Control of Plasticity and Fate Decision during CD8+T-Cell Memory Differentiation. *Cold Spring Harbor Perspectives in Biology*. Cold Spring Harbor Laboratory Press; 2021 May 10;13(12). Available from: <https://doi.org/10.1101/cshperspect.a037754>
178. DiNardo AR, Rajapakshe K, Nishiguchi T, Grimm SL, Mtetwa G, Dlamini Q, et al. DNA hypermethylation during tuberculosis dampens host immune responsiveness. *Journal of Clinical Investigation*. 2020 Mar 10;130(6):3113–23. <https://doi.org/10.1172/jci134622>
179. Metzemaekers M, Rinzema NJ, Stadhouders R. Epigenetic priming as a driver of memory recall and dysfunction in T cells. *The Journal of Experimental Medicine*. 2025 July 31;222(9). Available from: <https://doi.org/10.1084/jem.20241433>
180. Rose JR, Akdogan-Ozdilek B, Rahmberg AR, Powell MD, Hicks SL, Scharer CD, et al. Distinct transcriptomic and epigenomic modalities underpin human memory T cell subsets and their activation potential. *Communications Biology*. 2023 Apr 3;6(1). Available from: <https://doi.org/10.1038/s42003-023-04747-9>
181. Muroyama Y, Wherry EJ. Memory T-Cell Heterogeneity and Terminology. *Cold Spring Harbor Perspectives in Biology*. Cold Spring Harbor Laboratory Press; 2021 Mar 29;13(10). Available from: <https://doi.org/10.1101/cshperspect.a037929>
182. Montacchiesi G, Pace L. Epigenetics and CD8+ T cell memory*. *Immunological Reviews*. 2021 Dec 18;305(1):77–89. <https://doi.org/10.1111/imr.13057>
183. Zebley CC, Akondy R, Youngblood B, Kissick H. Defining the Molecular Hallmarks of T-Cell Memory. *Cold Spring Harbor Perspectives in Biology*. 2021 June 14;14(3). Available from: <https://doi.org/10.1101/cshperspect.a037804>
184. Peng S, Lin A, Jiang A, Zhang C, Zhang J, Cheng Q, et al. CTLs heterogeneity and plasticity: implications for cancer immunotherapy. *Molecular Cancer*. 2024 Mar 21;23(1). Available from: <https://doi.org/10.1186/s12943-024-01972-6>

185. Li W, Zhang L. Rewiring Mitochondrial Metabolism for CD8+ T Cell Memory Formation and Effective Cancer Immunotherapy. *Frontiers in Immunology*. Frontiers Media; 2020 Aug 27;11. <https://doi.org/10.3389/fimmu.2020.01834>
186. Devenish LP, Mhlana MM, Negishi Y. Immune Regulation in Time and Space: The Role of Local- and Long-Range Genomic Interactions in Regulating Immune Responses. *Frontiers in Immunology*. Frontiers Media; 2021 May 11;12. Available from: <https://doi.org/10.3389/fimmu.2021.662565>
187. Liu Q, Sun Z, Chen L. Memory T cells: strategies for optimizing tumor immunotherapy. *Protein & Cell*. Springer Science+Business Media; 2020 Mar 27;11(8):549–64. Available from: <https://doi.org/10.1007/s13238-020-00707-9>
188. Zhang Z, Butler RA, Koestler DC, Bell-Glenn S, Warriar G, Molinaro AM, et al. Comparative analysis of the DNA methylation landscape in CD4, CD8, and B memory lineages. *Clinical Epigenetics*. 2022 Dec 1;14(1). <https://doi.org/10.1186/s13148-022-01399-0>
189. Xiong D, Zhang L, Sun Z. Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. *Military Medical Research*. BioMed Central; 2023 Dec 4 10(1). Available from: <https://doi.org/10.1186/s40779-023-00496-2>
190. Lan Z, Chen Z, Yang N, Liu T, Li S, Shi Y, et al. Epigenetic control of tissue resident memory T cells. *Frontiers in Immunology*. Frontiers Media; 2025 Aug 15;16. Available from: <https://doi.org/10.3389/fimmu.2025.1605972>
191. Frias AB, Boi SK, Lan X, Youngblood B. Epigenetic regulation of T cell adaptive immunity. *Immunological Reviews*. 2021 Feb 28;300(1):9–21. Available from: <https://doi.org/10.1111/imr.12943>
192. Guo T, Li W, Cai X. Applications of Single-Cell Omics to Dissect Tumor Microenvironment. *Frontiers in Genetics*. Frontiers Media; 2020 Nov 27;11. Available from: <https://doi.org/10.3389/fgene.2020.548719>
193. Liu R, Zhao E, Yu H, Yuan C, Abbas MN, Cui H. Methylation across the central dogma in health and diseases: new therapeutic strategies. *Signal Transduction and Targeted Therapy*. Springer Nature; 2023 Aug 24;8(1). Available from: <https://doi.org/10.1038/s41392-023-01528-y>
194. Cheng B, Yu Q, Wang W. Intimate communications within the tumor microenvironment: stromal factors function as an orchestra. *Journal of Biomedical Science*. BioMed Central; 2023 Jan 4;30(1). <https://doi.org/10.1186/s12929-022-00894-z>
195. Niborski LL, Gueguen P, Ye M, Thiolat A, Ramos RN, Caudana P, et al. CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas. *Nature Communications*. 2022 June 29;13(1). <https://doi.org/10.1038/s41467-022-31504-z>

196. Li S, Hao L, Zhang J, Deng J, Hu X. Focus on T cell exhaustion: new advances in traditional Chinese medicine in infection and cancer. Chinese Medicine. BioMed Central; 2023 June 24;18(1). <https://doi.org/10.1186/s13020-023-00785-x>
197. Wong W, Yin B, Lam CYK, Huang Y, Yan J, Tan Z, et al. The Interplay Between Epigenetic Regulation and CD8+ T Cell Differentiation/Exhaustion for T Cell Immunotherapy. Frontiers in Cell and Developmental Biology. 2022 Jan 11;9:783227–783227. Available from: <https://doi.org/10.3389/fcell.2021.783227>
198. Torres L, Simone B, Campos T, Goepfert-Waterman E, Shestova O, Manne S, et al. Divergent exhaustion networks define memory CD8+ T cell subset fate under chronic stimulation and reveal targets for epigenetic reprogramming. Blood. 2025 Nov 3;146:4777–4777. Available from: <https://doi.org/10.1182/blood-2025-4777>
199. Niborski LL, Guéguen P, Ye M, Thiolat A, Ramos RN, Caudana P, et al. Epigenetic control of CD8+ T cell responsiveness to a-PD-1 by Suv39h1. HAL (Le Centre pour la Communication Scientifique Directe). 2020 Dec 4; <https://hal.science/hal-03041343>
200. Yousif A, Saadey AA, Lowin A, Castillo C, Saini A, Chan WK, et al. Modulating the epigenetic interplay in exhausted CD8 T cells for effective immunotherapy. The Journal of Immunology. 2024 May 1;212. Available from: <https://doi.org/10.4049/jimmunol.212.suppl.1492.6003>
201. Wu Y, Wu Y, Gao Z, Yu W, Zhang L, Zhou F. Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion. Signal Transduction and Targeted Therapy. 2026 Jan 1;11(1):2–2. <https://doi.org/10.1038/s41392-025-02327-3>
202. Jenkins E, Whitehead T, Fellermeier M, Davis SJ, Sharma S. The current state and future of T-cell exhaustion research. Oxford Open Immunology. 2023 Jan 1;4(1). Available from: <https://doi.org/10.1093/oxfimm/iqad006>
203. Quezada LK, Jin W, Liu YC, Kim ES, He Z, Indralingam CS, et al. Early transcriptional and epigenetic divergence of CD8+ T cells responding to acute versus chronic infection. PLoS Biology. 2023 Jan 30;21(1). Available from: <https://doi.org/10.1371/journal.pbio.3001983>
204. Stairiker CJ, Thomas GD, Salek-Ardakani S. EZH2 as a Regulator of CD8+ T Cell Fate and Function. Frontiers in Immunology. Frontiers Media; 2020 Oct 6;11. Available from: <https://doi.org/10.3389/fimmu.2020.593203>
205. Maes K, Mondino A, Lasarte JJ, Agirre X, Vanderkerken K, Prósper F, et al. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. Frontiers in Immunology. Frontiers Media; 2021 Mar 30;12. Available from: <https://doi.org/10.3389/fimmu.2021.652160>
206. Zhou L, Xu N, Shibata H, Saloura V, Uppaluri R. Epigenetic modulation of immunotherapy and implications in head and neck cancer. Cancer and Metastasis Reviews. Springer Science+Business Media; 2021 Jan 5;40(1):141–52. Available from: <https://doi.org/10.1007/s10555-020-09944-0>

207. Huang J, Zhang J, Guo Z, Li C, Tan Z, Wang J, et al. Easy or Not—The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity. *Frontiers in Immunology*. Frontiers Media; 2021 Oct 19;12. Available from: <https://doi.org/10.3389/fimmu.2021.741302>
208. Karin M, Shalapour S. Regulation of antitumor immunity by inflammation-induced epigenetic alterations. *Cellular and Molecular Immunology*. Springer Nature; 2021 Aug 31;19(1):59–66. <https://doi.org/10.1038/s41423-021-00756-y>
209. DiNardo AR, Netea MG, Musher DM. Postinfectious Epigenetic Immune Modifications — A Double-Edged Sword. *New England Journal of Medicine*. Massachusetts Medical Society; 2021 Jan 20;384(3):261–70. Available from: <https://doi.org/10.1056/nejmra2028358>
210. Samareh P, Agudelo-Garcia PA, Zhang Z, Gilbert M, Mendoza M, Huang H, et al. Chromatin repression by PRC2 results in reduced gene expression driving key features of CD8 T cell exhaustion. *The Journal of Immunology*. 2025 Aug 7 ;214(11):2987–3002. Available from: <https://doi.org/10.1093/jimmun/vkaf188>
211. Cheng H, Qiu Y, Xu Y, Chen L, Ma K, Tao M, et al. Extracellular acidosis restricts one-carbon metabolism and preserves T cell stemness. *Nature Metabolism*. 2023 Jan 30;5(2):314–30. <https://doi.org/10.1038/s42255-022-00730-6>
212. Hou Y, Žák J, Shi Y, Pratumchai I, Dinner B, Wang W, et al. Transient EZH2 suppression by Tazemetostat during in vitro expansion maintains T cell stemness and improves adoptive T cell therapy. 2023 Feb 7; <https://doi.org/10.1101/2023.02.07.527459>
213. Hou Y, Žák J, Shi Y, Pratumchai I, Dinner B, Wang W, et al. Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy. *Cancer Immunology Research*. 2024 Oct 4;13(1):47–65. Available from: <https://doi.org/10.1158/2326-6066.cir-24-0089>
214. Hou Y, Wu P, PI. 811 Transient EZH2 suppression by tazemetostat during in vitro expansion maintains T cell stemness and improves adoptive T cell therapy. *Regular and Young Investigator Award Abstracts*. 2023 Oct 31; Available from: <https://doi.org/10.1136/jtc-2023-sitc2023.0811>
215. Hou Y, Žák J, Shi Y, Pratumchai I, Dinner B, Wang W, et al. Data from Transient EZH2 Suppression by Tazemetostat during *In Vitro* Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy. 2025 Jan 9; <https://doi.org/10.1158/2326-6066.c.7618111>
216. Hou Y, Wu P. Abstract LB339: Transient EZH2 suppression by tazemetostat during in vitro expansion maintains T cell stemness and improves adoptive T cell therapy. *Cancer Research*. 2024 Apr 5;84. <http://dx.doi.org/10.1158/1538-7445.am2024-lb339>

217. Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Molecular Cancer. BioMed Central; 2021 Dec 20;20(1). <https://doi.org/10.1186/s12943-021-01464-x>